AlloDerm Co-Promotion Agreement between Obagi Medical Products, Inc. and LifeCell Corporation

Contract Categories: Business Operations › Collaboration Agreements
Summary

Obagi Medical Products, Inc. and LifeCell Corporation have entered into an agreement granting Obagi exclusive rights to co-promote Micronized AlloDerm, a tissue regeneration product, in specified markets and regions. LifeCell retains ownership of the product and provides Obagi with distribution rights for a set term. The agreement outlines each party’s responsibilities, including sales, distribution, and financial arrangements, and specifies the markets and customer groups covered. The contract also addresses intellectual property, improvements, and conditions for exclusivity.

View More
EX-10.8 10 a2028118zex-10_8.txt EXHIBIT 10.8 ALLODERM-Registered Trademark- CO-PROMOTION AGREEMENT THIS ALLODERM CO-PROMOTION AGREEMENT (the "Agreement") is made and entered into this 9th day of February, 2000 (the "Effective Date"), by and between Obagi Medical Products, Inc. ("OMP"), a California corporation, and LifeCell Corporation. ("LifeCell"), a Delaware corporation. OMP and LifeCell are collectively referred to as the "Parties." RECITALS WHEREAS, LifeCell is a bioengineering company engaged in the development and commercialization of tissue regeneration and cell preservation products and holds all right, title and interest in and to AlloDerm acellular dermal graft ("AlloDerm-Registered Trademark-"); WHEREAS, AlloDerm is prepared in two forms: prepackaged for injection in several sizes of syringes ("Micronized AlloDerm-TM-"), and prepackaged in several sizes in sheet form, and this Agreement relates only to Micronized AlloDerm-TM-; WHEREAS, OMP desires to secure exclusive rights from LifeCell for a specific term for the co-promotion of the Products in specified markets in identified geographic regions pursuant to the terms and conditions herein provided; and WHEREAS, LifeCell desires to provide exclusive rights to OMP for a specific term for the co-promotion of the Products (as defined in Section 1) in specified markets in identified geographic regions pursuant to the terms and conditions herein provided; NOW, THEREFORE, in consideration of the mutual covenants and promises recited below, the parties, intending to be legally bound, agree as follows: TERMS AND CONDITIONS I. DEFINITIONS As used in this Agreement, the following capitalized terms shall have the following respective meanings: "AFFILIATE" shall mean (a) any company owned or controlled to the extent of at least fifty percent (50%) of its issued and voting capital securities by a party to this Agreement and any other company so owned or controlled (directly or indirectly) by any such company or the owner of any such company, or (b) any partnership, joint venture or other entity directly or indirectly controlled by, controlling, or under common control of, to the extent of fifty percent (50%) or more of voting power (or otherwise having power to control its general activities) by a party to this Agreement, but in each case only for so long as such ownership or control shall continue. "cc" shall mean the unit of volume equal to one (1) cubic centimeter. "COMPETITIVE PRODUCTS" shall mean injectable augmentation products used in reconstructive plastic surgery by office-based dermatologists and office-based plastic surgeons. "CONTRACT YEAR" shall mean each consecutive twelve month period, with the first Contract Year beginning on January 1, 2000. "COST OF GOODS SOLD" shall mean LifeCell's manufacturing cost for each Unit of Product including direct labor, direct material and manufacturing overhead allocated on a basis consistent with all of LifeCell's finished goods, but excluding any extraordinary or non-recurring charges, and expenses or costs related to the start-up of manufacturing of Micronized AlloDerm-TM- in commercial quantities. "COST OF GOODS SOLD PERCENTAGE" shall mean the average, for any six (6) consecutive months, of the Cost of Goods Sold per Unit divided by the Net Sales Per Unit. "DATE OF COMMERCIALIZATION" shall mean the calendar date three business days after LifeCell first ships any Product to OMP. "DISTRIBUTION AMOUNT" shall mean [***]% of Net Sales, retained by OMP to offset costs of distribution. "DOLLAR", "DOLLARS" or "$" shall mean the legal currency of the United States of America. "HOLD BACK AMOUNT" shall mean, for the initial Contract Year, the percentage of the LifeCell Amount equal to OMP's reserve for bad debts, as determined in accordance with United States generally accepted accounting principles, expressed as a percentage of OMP's accounts receivable with respect to the end of the immediately preceding fiscal year. The Initial Hold Back Amount shall be [***] percent ([***]%). The Hold Back Amount for all subsequent Contract Years shall mean the percentage of the LifeCell Amount equal to OMP's Actual Bad Debt (as defined below) directly related to the sale of Product for the immediately preceding Contract Year expressed as a percentage of OMP's accounts receivable with respect to the sale of Product. "Actual Bad Debt" shall mean OMP's customer accounts for the sale of Product for which payments are one hundred and twenty (120) days or more past due, and actually written off against OMP's bad debt reserve account. "IMPROVEMENT" means any information, discovery, creation, derivative work, invention, or trade secret, whether or not patented or patentable or copyrighted or copyrightable, respecting the Product or derived from human cadaveric dermis, that is developed or otherwise acquired by either party, their Affiliates or any of their respective employees, officers or agents. "INDEMNIFIABLE DAMAGES" shall mean the sum of all losses, claims, damages, liabilities, costs, expenses or deficiencies described in Article X. -2- [***] Material has been omitted pursuant to a request for confidential treatment and such material has been filed separately with the Securities and Exchange Commission. "INTELLECTUAL PROPERTY" shall mean (i) patents and patent applications, (ii) trademarks, trade names, service marks and registrations and applications for registrations thereof (including, but not limited to, "AlloDerm-Registered Trademark-," "Cymetra-TM-" and analogs thereof), (iii) copyrights and copyright registrations, (iv) trade secrets and secret processes, and (v) other Know-How, in each case relating to the Product and in the United States of America and the Territory. "JOINT MANAGEMENT COMMITTEE" shall mean the committee formed pursuant to Article V of this Agreement. "KNOW-HOW" shall mean such know-how, special knowledge, data, studies, technical or other information, whether or not patented or patentable, owned or controlled by LifeCell at any time prior to or during the Term specifically related to the Product. "LIFECELL AMOUNT" shall mean the amount of all Payable Sales made by OMP on behalf of LifeCell in any month reduced by the amounts, if any, retained by OMP for co-promotion fees due to OMP, as calculated in accordance with Sections 3.3 and 3.4. "NET SALES" shall mean the gross revenue recognized from sales of Product less the amount for returns and allowances as determined in accordance with generally accepted accounting principles. "PAYABLE SALES" shall mean the amount of Net Sales, reduced by the Distribution Amount. "PRODUCT" shall mean Micronized AlloDerm-TM- and any Improvement. Upon the granting of any licenses and rights as contemplated by Section 2.4 and executing and delivering any amendment of this Agreement as contemplated by Section 2.4, such additional products for which such license is granted shall thereafter also be deemed Product. "SPECIFICATIONS" shall mean the Product specifications set forth in Exhibit B annexed hereto and incorporated herein. "TERRITORY" shall mean only office-based dermatologists and office-based plastic surgeons throughout the entire world, as may be modified by mutual agreement of the Parties pursuant to Section 2.3, PROVIDED, HOWEVER, that LifeCell's customers, as set forth in Exhibit D annexed hereto and incorporated herein, are specifically excluded from the Territory. Notwithstanding any other provision of this Agreement, LifeCell shall retain the exclusive right to distribute Product in Korea and Brazil, with no rights to transship from these countries, provided that all Product sold into Korea and Brazil shall be included in the Minimum Annual Sales of Units sold by OMP pursuant to section 4.1. "UNIT" shall mean an individual unit of Product packaged in accordance with specifications provided by OMP from time to time and reasonably acceptable to LifeCell. One Unit of Micronized AlloDerm-TM- shall be equal to 330 milligrams of Micronized AlloDerm-TM- measured on a dry weight basis which is to be reconstituted with one cc of diluent. -3- II. GRANT OF RIGHTS 2.1 GRANT OF RIGHTS; TERRITORY. In consideration for the execution and delivery of this Agreement and the ongoing performance by OMP of its responsibilities and obligations hereunder, and upon the terms and conditions set forth herein, LifeCell hereby grants to OMP the exclusive right to promote, market, distribute and sell Micronized AlloDerm-TM- and any Improvement thereto in the Territory, consistent with the terms and conditions set forth herein, throughout the Term (as defined in Section 13.1). Except as expressly set forth herein, the license granted hereby expressly excludes all other rights, including without limitation, the right to manufacture any Product. 2.2 INTENTIONALLY DELETED 2.3 ADDITIONAL TERRITORY. In the event the Parties reach agreement with respect to the terms and conditions of granting OMP the rights to promote, market, distribute, and sell the Product in any additional market segment, pursuant to this Section 2.3, the Parties shall amend this Agreement to incorporate the terms of such additional terms and conditions into this Agreement; PROVIDED, HOWEVER, the Parties agree that the revenue allocations as set forth in Article III shall not be changed as a result of such amendment. 2.4 ADDITIONAL PRODUCTS. LifeCell agrees that it will not enter into any exclusive agreement with any third party for any rights to promote, market, distribute and sell any and all new products substantially similar to the Product (including, without limitation, any new injectable tissue augmentation products and any new products which are substantially similar to the Product but offered in a different delivery platform), without first providing ten (10) days written notice to OMP. OMP may, within five (5) business days of receiving such notice, provide written notice to LifeCell indicating OMP's interest in obtaining such exclusive rights. Thereafter, the Parties shall meet and use reasonable commercial efforts to reach a mutually acceptable agreement. Nothing contained in this Agreement obligates LifeCell or OMP to enter into such an agreement and either party may terminate negotiations concerning such an agreement at its sole and exclusive option. III. SALES; REVENUE ALLOCATION 3.1 ONE-TIME PAYMENTS. In consideration of the exclusive licenses and rights set forth in this Agreement, OMP shall pay LifeCell One Million Dollars ($1,000,000), payable as follows: (a) Four Hundred Thousand Dollars ($400,000) in immediately available funds on the Effective Date. (b) Six Hundred Thousand Dollars ($600,000) in immediately available funds on the later of either (i) June 30, 2000 or (ii) the date ninety (90) days following the Date of Commercialization; -4- 3.2 SALES REPRESENTATIVE. OMP shall act as LifeCell's exclusive representative in the Territory with respect to sales of Product pursuant to this Agreement. All revenues obtained from the sales of Product pursuant to this Agreement shall be for the account of LifeCell and all accounts receivable related to such sales shall be accounts receivable of LifeCell. The Parties agree that LifeCell will record the Net Sales of Product on LifeCell's financial statements, but that OMP shall be responsible, at its sole cost and expense, for billing customers and collecting the accounts receivable from such customers. OMP shall not, without the prior written approval of LifeCell, sell any Product to customers that are over fifty-nine (59) days past due on their accounts. OMP will endeavor to include in its Product invoice a notation to the effect that the Product is distributed by OMP as distributor for LifeCell. 3.3 INTENTIONALLY DELETED 3.4 MICRONIZED ALLODERM-TM- REVENUE ALLOCATION. OMP shall be entitled to a co-promotion fee for sales of Micronized AlloDerm-TM- according to the following schedule:
- ------------------------------------------------------- ----------------------------------------------------- Annual Units OMP Co-Promotion fee as a Percentage of One (1) Unit equals 330 mgs per cc Payable Sales - ------------------------------------------------------- ----------------------------------------------------- [***]-[***] [***]% - ------------------------------------------------------- ----------------------------------------------------- [***] to [***] [***]% - ------------------------------------------------------- ----------------------------------------------------- [***] and above [***]% - ------------------------------------------------------- -----------------------------------------------------
The Co-Promotion fee is predicated on a Cost of Goods Sold Percentage not exceeding [***]%. If the Cost of Goods Sold Percentage exceeds [***]%, then LifeCell's continuing obligation to supply Product under the terms of this Agreement shall be limited to the 100,000 Units during the succeeding four calendar quarters. Further, in this event, the parties agree to use commercially reasonable efforts to re-negotiate the Co-Promotion Fee payable. 3.5 MONTHLY PAYMENTS AND REPORTING. On or before the forty-fifth (45th) day immediately following the last day of each calendar month during the Term, OMP shall pay to LifeCell the LifeCell Amount less the Hold Back Amount for that calendar month. OMP shall, on or before the tenth (10th) day of each month, provide to LifeCell a written report of Net Sales of Products made for the prior month, setting forth in reasonably sufficient detail the sales price and Unit(s) of Product ordered and sold and the calculation of the amounts paid to LifeCell and the co-promotion fees due and retained by OMP, if any. The payment to LifeCell pursuant to this Section shall be made by check or by wire transfer of immediately available funds, pursuant to such written wire transfer instructions as LifeCell may provide to OMP from time to time during the Term. In addition to any other remedies available to LifeCell arising out of OMP's payment default, if any payment is more than fifteen days (15) late, OMP shall pay to LifeCell a late charge on the overdue balance equal to the lesser of (1) 1 1/2% per month or (ii) the highest rate permitted by applicable law. -5- [***] Material has been omitted pursuant to a request for confidential treatment and such material has been filed separately with the Securities and Exchange Commission. 3.6 TRUE-UP OF HOLD BACK AMOUNT. No later than sixty (60) days after the last day of each Contract Year, OMP shall provide LifeCell with a written report detailing the Actual Bad Debt incurred by OMP (the "Bad Debt Report"). Such Bad Debt Report shall include, without limitation, information concerning payment history on applicable OMP customer accounts and a summary of the Actual Bad Debt amounts (including a calculation of the percentage of Actual Bad Debt as compared to total gross sales of Product) as of the end of the applicable Contract Year. If the Actual Bad Debt exceeds the applicable Hold Back Amount, LifeCell shall, within ten (10) business days after delivery of the Bad Debt Report, reimburse OMP, in immediately available funds, for the difference between the Hold Back Amount and the Actual Bad Debt for such Contract Year. If the Actual Bad Debt does not exceed the Hold Back Amount for such Contract Year, OMP shall, within ten (10) business days after delivery of the Bad Debt Report, remit to LifeCell the difference, if any, between the Hold Back Amount and the Actual Bad Debt. Notwithstanding anything to the contrary contained herein, if the Hold Back Amount or Actual Bad Debt amount exceeds [***] percent ([***]%) of the gross sales of Product for any applicable Contract Year, LifeCell may terminate this Agreement in accordance with Section 13.2. 3.7 PRODUCT STORAGE, HANDLING, TRANSPORT AND RECORDS. OMP shall store, handle and transport the Product, and prepare, maintain and retain all records regarding such matters and OMP's distribution of Product in accordance with (i) all applicable legal requirements then in effect, including without limitation, the regulations of the United States Food and Drug Administration ("FDA") and the United States Department of Health and Human Services (21 C.F.R. Part 1270), (ii) the Guidelines of the American Association of Tissue Banks and (iii) the specifications and procedures set forth on Exhibit E annexed hereto and incorporated herein, as such exhibit may be revised from time to time upon mutual agreement of the Parties or as required by applicable laws, rules or regulations. 3.8 RECORDS; AUDIT RIGHTS. Each party shall keep books and records sufficient to verify the accuracy and completeness of all activities in connection with this Agreement, including without limitation, inventory, shipping and delivery, storing, handling, transport, costs, sales, purchase and invoice records relating to the Product. Such books and records shall be preserved for a period not less than ten (10) years after they are created during and after the Term. Either party may, upon not less than fifteen (15) business days advance written notice, audit all the books and records of the other party relating to this Agreement at a single United States location to verify the accuracy of such party's accounting. Any audit performed pursuant to this Section 3.8 shall be at expense of the party conducting such audit, unless it reveals a underpayment or overpayment of five per cent (5%) or more in favor of the audited party for any Contract year, in which case the audited party shall reimburse the auditing party for the actual costs of such audit. Such audit may be performed by any employee of the requesting party as well as by any attorney or licensed certified public accountant designated by the requesting party, upon not less than fifteen (15) business days advance notice, during regular business hours, and in a manner that shall not unreasonably interfere with such party's normal business operations. Each party shall conduct no more than one (1) audit during any Contract Year, PROVIDED, HOWEVER, that such audit shall not be limited to the current Contract Year, but shall be limited to the period since the completion of the immediately preceding audit, if any. If an audit reveals any underpayment by OMP to LifeCell, OMP shall pay LifeCell the amount of such -6- [***] Material has been omitted pursuant to a request for confidential treatment and such material has been filed separately with the Securities and Exchange Commission. underpayment within five (5) days of written notification of such underpayment. If the audit reveals that OMP has made an overpayment to LifeCell, the amount overpaid will be, at the option of OMP, returned forthwith to OMP or credited to the next such payment or payments due OMP from LifeCell. IV. MINIMUM SALES AMOUNTS 4.1 MICRONIZED ALLODERM-TM-. On or before the last day of each Contract Year set forth in the chart below, OMP shall attain either (i) the Minimum Annual Sales amount of Micronized AlloDerm-TM- within that specific Contract Year as set forth in the table below, or (ii) attain the Total Cumulative Units of Micronized AlloDerm-TM- sold by the last day of the Contract Year, as set forth in the table below, provided, however, that if the Date of Commercialization does not occur on or before June 30, 2000, the amounts set forth in the table below for Year One, Year Two and the Total Cumulative Units Sold for Years Two, Three, Four and Five will be reduced to the amount which is prorated on an annual basis for each day after June 30, 2000 until the actual Date of Commercialization in order to take into account the lesser time available for OMP to achieve the minimum amounts set forth below.
- --------------------------------- --------------------------------------- ------------------------------- Contract Year Minimum Annual Sales Total Cumulative Units Sold Units Sold - --------------------------------- --------------------------------------- ------------------------------- Year One [***] [***] - --------------------------------- --------------------------------------- ------------------------------- Year Two [***] [***] - --------------------------------- --------------------------------------- ------------------------------- Year Three [***] [***] - --------------------------------- --------------------------------------- ------------------------------- Year Four [***] [***] - --------------------------------- --------------------------------------- ------------------------------- Year Five [***] [***] - --------------------------------- --------------------------------------- -------------------------------
4.2 FAILURE TO ATTAIN MINIMUM LEVELS. In the event that OMP fails to meet the obligations set forth in Section 4.1 in any specific Contract Year, OMP, shall pay to LifeCell in immediately available funds, not later than thirty (30) after the last day of such Contract Year, [***]% of the difference between (1) the LifeCell Amount that would have been due to LifeCell for and as of the last day of such Contract Year had the obligations set forth in Sections 4.1 been achieved by OMP (the "Minimum Sales Payment") and (2) any LifeCell Amount actual paid to LifeCell in respect of such Contract year. In the event that OMP fails to pay to LifeCell an amount equal to or greater than the Minimum Sales Payment in any Contract Year, LifeCell, at its sole and exclusive option, may (i) immediately terminate the exclusive rights granted to OMP in Section 2.1, with such exclusive rights becoming immediately non-exclusive, or (ii) terminate this Agreement in accordance with Section 13.2. 4.3 COMPETITIVE PRODUCTS. If, in any Contract Year, the Net Sales of Competitive Products offered by OMP exceeds twenty-five percent (25%) of the sum of total sales of the Product by OMP and the total sales of Competitive Products offered by OMP, LifeCell, at its -7- [***] Material has been omitted pursuant to a request for confidential treatment and such material has been filed separately with the Securities and Exchange Commission. sole and exclusive option, may immediately terminate the exclusive rights granted to OMP in Section 2.1, with such exclusive rights becoming immediately non-exclusive. V. JOINT MANAGEMENT COMMITTEE 5.1 STRUCTURE; SCOPE OF RESPONSIBILITY. Within thirty (30) days after the Effective Date, the Parties shall establish a Joint Management Committee with an equal number of members from OMP and LifeCell. The Joint Management Committee will consist of four (4) persons. Each party shall provide the other party with written notice of the two (2) representatives that such party is appointing to serve on the Joint Management Committee, and each party shall retain sole authority to remove its representatives from the Joint Management Committee and to appoint successors, by providing written notice to the other party. The Joint Management Committee will facilitate a sharing of information related to the Product and the respective obligations of the Parties pursuant to this Agreement. The Joint Management Committee shall have the responsibility to coordinate the creation of an annual marketing plan and certain activities of the Parties pursuant to this Agreement, including those related to the marketing, sales and co-promotion of the Product, and such other matters as the Parties may mutually agree upon from time to time. Furthermore, the Joint Management Committee shall use commercially reasonable efforts to set the Price for the Product. 5.2 DETERMINATION OF MARKET ENTRY. Within ninety (90) days after the Effective Date, the Parties shall meet, at a date, time and location to be designated by the Joint Management Committee, to evaluate the feasibility, timing and requirements for market entry to introduce Micronized AlloDerm-TM- into some or all of the countries outside of the United States that contain significant market opportunities for the sale of the Product. 5.3 PRODUCT CLASSIFICATION. As of the Effective Date, the FDA has classified the Product as banked human tissue. The Parties acknowledge and agree that, under the Federal Food, Drug and Cosmetic Act and regulations promulgated thereunder, the FDA could at some future time determine that the Product is a medical device for the intended uses contemplated in this Agreement rather than human tissue. The Parties also acknowledge and agree that LifeCell does not warrant that the Product currently meets or in the future will meet medical device regulatory requirements, including without limitation, that the Product will not have obtained premarket approval. The Parties further acknowledge and agree that the FDA's imposition of medical device regulatory requirements would be substantially more burdensome and costly than the FDA's human tissue regulatory requirements and that, among other things, the FDA could require that a party or the Parties take certain actions with respect to the Product regarding premarket approval, commercial distribution and regulatory requirements that could have a material impact on the obligations of the Parties hereunder. In the event that the Joint Management Committee decides to recommend a change to the regulatory classification, the Joint Management Committee shall be responsible for recommending the extent of clinical testing and the regulatory strategy for the Products. Notwithstanding anything contained herein to the contrary, the Parties acknowledge and agree that LifeCell shall not be under any obligation under this Agreement to meet or otherwise satisfy the medical device regulatory requirements. In the event that the FDA undertakes any action altering the regulatory classification of the Product, -8- and such action has a material adverse effect on the rights or obligations of the Parties pursuant to this Agreement (including, without limitation, (a) the commercial viability of any Product and (b) the legal authority or ability of either party to perform its obligations pursuant to this Agreement), the Parties' obligations pursuant to this Agreement with respect to such adversely affected Product shall, in the sole discretion of LifeCell, be voided or alternatively suspended for so long as the commercial viability of such Product is affected and the various rights related to such Product (including those of exclusivity) granted to OMP in this Agreement shall be extended for a period of time equal to the length of time that such Product was adversely affected. VI. QUALITY ASSURANCE AND ADVERSE EVENT REPORTING. 6.1 QUALITY COMPLAINTS. Product quality complaints received by OMP shall be forwarded upon receipt to a quality assurance representative to be designated by LifeCell. LifeCell retains sole responsibility to investigate these complaints throughout the Term and to provide OMP with a follow-up report and required corrective actions, if any, within thirty (30) days of receipt of such notice. 6.2 ADVERSE EVENTS. Adverse event reports received by OMP shall be forwarded upon receipt to LifeCell's designated quality assurance representative. LifeCell has sole responsibility to fulfill the appropriate regulatory and reporting requirements related to the adverse event reports throughout the Term. 6.3 COMPLAINTS. In the event that LifeCell or OMP receives any complaint, claim or adverse event report relating to the Product, including notices from the FDA regarding any alleged regulatory non-compliance of such Product or the marketing of such Product, such party shall, within ten (10) days following receipt of such notices, or such shorter period as may be required by applicable laws, rules or regulations, provide to the other party all information contained in such complaint, report or notice and any additional information relating thereto as may reasonably be requested. 6.4 REGULATORY NOTICES. Each of LifeCell and OMP shall promptly, but in no event more than five (5) days following the receipt thereof, notify the other party and provide to such party a copy or transcription, if available, of any communication received from a regulatory agency relating to the Product, the marketing thereof, of any matter related thereto. 6.5 AUDIT OF ADVERSE EVENT REPORTS AND PRODUCT RECALL RECORDS: (a) Upon reasonable notice and during regular business hours, OMP shall make available the records relating to quality complaints referred to in Section 6.1, adverse events referred to in Section 6.2, complaints referred to in 6.3, and regulatory notices referred to in Section 6.4 for audit at LifeCell's expense by independent representatives selected by LifeCell or qualified LifeCell employees to verify compliance with the applicable provisions hereof. -9- (b) Upon reasonable notice and during regular business hours, LifeCell shall make available the records relating to quality complaints referred to in Section 6.1, adverse events referred to in Section 6.2, complaints referred to in 6.3, and regulatory notices referred to in Section 6.4 for audit at OMP's expense by independent representatives selected by OMP or qualified OMP employees to verify compliance with the applicable provisions hereof. VII. MARKETING, SALES AND CLINICAL TRIALS. 7.1 LIFECELL RIGHTS AND RESPONSIBILITY. In the event the Joint Management Committee is unable to agree upon the price of the Product, LifeCell shall have the sole right to set the price for the Product, and further LifeCell shall have the sole right to review and approve any preclinical and clinical activities undertaken by OMP with respect to the Product. 7.2 OMP RESPONSIBILITY. OMP shall, at its sole cost and expense, make reasonable efforts to maintain sufficient promotional, marketing, sales, and distribution capacity to meet the demands of the marketplace for the Products and to promote and market the Micronized AlloDerm-TM- in the Territory, including without limitation: (a) the creation, preparation and production of promotional materials related to the Product; (b) the creation and implementation of an advertising campaign to promote the Product; (c) maintaining and compensating a reasonably sufficient number of qualified salespersons to promote and market the Micronized AlloDerm-TM- in the Territory. 7.3 PRODUCT PACKAGING. Products manufactured and delivered pursuant to this Agreement shall be labeled in a manner to indicate that the Product is distributed by OMP for LifeCell and such Product shall be packaged in a separate trade dress to facilitate product tracking. The Parties agree that the brand name for the Micronized AlloDerm-TM- shall be "Cymetra-TM-." All right, title and interest in the name "Cymetra-TM-" shall reside in LifeCell, and OMP expressly agrees that it neither has nor shall it acquire rights in the name "Cymetra-TM-" except as expressly set forth in this Agreement. Within thirty (30) days following the Effective Date, the Parties shall use diligent commercial efforts to reach mutual agreement on the final packaging for Product to be distributed pursuant to this Agreement. 7.4 LIFECELL USE OF MARKETING MATERIALS. OMP, upon LifeCell's request, shall make the Marketing Materials (as defined in Section 7.5) produced pursuant to this Article VII available to LifeCell for use in conjunction with the promotion, marketing, sales and distribution of the Product, and to remove OMP's name from such Marketing Materials. OMP shall provide the Marketing Materials to LifeCell at the actual cost of producing such materials, as incurred by OMP. -10- 7.5 TRADEMARK LICENSES. OMP hereby grants to LifeCell a non-exclusive, royalty-free right and license to utilize OMP's trademarks, service marks and trade names as necessary to package and label the Product to be manufactured by LifeCell pursuant to this Agreement (the "OMP Packaging License"), revocable in accordance with Section 13.4. LifeCell hereby grants to OMP a non-exclusive, royalty-free right and license to utilize LifeCell's trademarks, service marks and trade names as necessary to market, promote, sell and distribute the Product in the manner contemplated by this Agreement (the "LifeCell Mark License"), revocable in accordance with Section 13.4. The parties acknowledge and agree that all right, title and interest in and to any trademarks, service marks or trade names created for any product or Product developed or invented hereunder shall reside solely in LifeCell. 7.6 PRE-PUBLICATION REVIEW OF MARKETING MATERIALS. All Marketing Materials (as defined below) are expressly subject to pre-publication review and approval with respect to, but not limited to, content, style, appearance, composition, timing, and media. Prior to the distribution or publication of any materials containing any of LifeCell's trademarks, service marks or trade names ("Marketing Materials") OMP shall provide one copy of such Marketing Materials to LifeCell for final review and approval (Attention: _________, LifeCell Corporation, One Millennium Way, Branchburg, NJ 08876) at least twenty (20) days prior to the anticipated publication of such Marketing Materials. LifeCell agrees to promptly review such Marketing Materials, and LifeCell's failure to provide written notice of its objection to the use of any Marketing Materials within twenty (20) business days of their receipt shall constitute LifeCell's approval of such Marketing Materials. Notwithstanding anything to the contrary contained herein, OMP shall not use, distribute or publish anything containing LifeCell's trademarks, service marks or trade names without the express prior written consent of LifeCell, provided, however that such consent shall be exercised consistent with this Section 7.6 and not unreasonably, withheld, conditioned or delayed. 7.7 MARKETING FOR PERMITTED USES. OMP shall market the Product solely for those uses for which the Product is permitted to be so marketed pursuant to FDA and all other applicable legal and regulatory requirements. VIII. SUPPLY; FORECASTS; ORDERS AND SHIPPING. 8.1 AGREE TO SUPPLY. Consistent with the current accepted Forecast Document (as defined in Section 8.2) and the terms and conditions set forth in this Agreement, LifeCell shall supply and deliver to OMP Product in such quantities as OMP requests during the Term of this Agreement, up to the amount forecasted for such time frame as set forth in the current Forecast Document. LifeCell shall deliver ordered Product to OMP on the date requested by OMP in such purchase order, but in no event shall LifeCell be obligated to ship any Product within less than thirty (30) days from the date of LifeCell's receipt of a valid written purchase order from OMP. All orders for Product shall be made pursuant to written purchase orders signed by an authorized representative of OMP and delivered to LifeCell in accordance with this Article VIII. All Product received from LifeCell will be held as consigned inventory for LifeCell. Title to the consigned inventory will remain with LifeCell until the time that OMP has delivered the Product to the customer and the invoice therefor, at which time title to such Product shall pass to the customer. -11- OMP will return to LifeCell for disposal any expired Product held as consigned inventory by OMP. 8.2 FORECASTS. Every thirty (30) days during the Term, OMP shall provide LifeCell with a good faith non-binding running estimate of the quantity of Product OMP reasonably estimates OMP will order and sell during each of the next twelve (12) months (but not extending beyond the Term) (the "Forecast Document"). OMP shall provide its initial forecast within thirty (30) days after the Effective Date. LifeCell shall have ten (10) days to review the Forecast Document. If, in LifeCell's good faith judgment, LifeCell will be unable to meet the amounts set forth in the Forecast Document, LifeCell shall provide written notice thereof to OMP, and the Parties shall negotiate in good faith an acceptable amount. If despite reasonable efforts, LifeCell is unable to supply adequate Product to meet the demands of OMP (as set forth in the Forecast Document), LifeCell and any third party licensee of the Product, then LifeCell shall use commercially reasonable efforts to devise an allocation system of existing supply to be reviewed monthly. If the Parties are unable to agree upon an allocation of available product, the matter shall be resolved in accordance with Section XIV. 8.3 ORDERS. Each OMP purchase order shall be in a form compatible with LifeCell's business form requirements and shall be subject to the terms and conditions of this Agreement. No printed term or provision contained in any OMP form or any LifeCell form which is inconsistent with or in addition to the terms of this Agreement shall be effective to alter the terms of this Agreement in any way unless agreed to in writing by both Parties. Each purchase order shall be subject to this Agreement and shall incorporate the terms and conditions of this Agreement. Each purchase order shall include at least the following information: the date of the order; the specific Product ordered; the quantity of each Product ordered; the price of the Product; and a delivery date for the order. 8.4 CANCELLATION OF ORDERS. OMP may, at no cost, cancel any purchase order at any time up to twenty (20) days prior to the shipping date set forth on such purchase order and may reschedule any order at any time up to twenty (20) days prior to the shipping date set forth on such purchase order. 8.5 DELIVERY. LifeCell shall use commercially reasonable efforts to ship orders according to the delivery date specified in each purchase order accepted by LifeCell. Notwithstanding the foregoing, LifeCell shall not be responsible for any delay in filling any purchase order due to a force majeure condition as set forth in Section 15.3. 8.6 SHIPPING. LifeCell shall ship Products, F.O.B. destination, to OMP's warehouse or such other OMP business location in the United States of America designated by OMP, in a final, packaged form, ready for immediately delivery to customers. 8.7 INSPECTION; ACCEPTANCE. OMP shall have the right to inspect the Product prior to sale to customers and shall notify LifeCell in writing of OMP's rejection of any Product due to the failure of the Product to meet Specifications. Such written notification by OMP shall include a detailed description of the test(s) that OMP performed on the Product and the results of such test(s). -12- LifeCell maintains the right to perform its own tests on Product rejected by OMP to determine if the Product meets Specifications. In the event that LifeCell's inspection verifies that the rejected Products failed to meet the applicable Specifications, LifeCell shall, in its sole discretion, either repair or replace all Product properly rejected under this Section 8.7. LifeCell shall bear the cost of shipping rejected Product back to LifeCell, as well as bear the cost of shipping replacement Product to OMP under this Section 8.7. In the event that LifeCell's inspection indicates that the Product does meet the applicable Specifications, LifeCell shall provide the results of its tests to OMP. In the event that the Parties are unable to reach agreement concerning Product rejected by OMP and which Product LifeCell's tests indicate conforms to applicable specifications, either party may invoke the dispute resolution procedure set forth in Article XIV. IX. REPRESENTATIONS AND WARRANTIES; RELATED MATTERS; LIMITATION OF LIABILITY 9.1 MUTUAL REPRESENTATIONS AND WARRANTIES. Each of the Parties represents and warrants to the other that: (a) it is duly organized, validly existing and in good standing in accordance with the laws of its jurisdiction of organization; (b) it has all requisite legal and corporate power and authority to enter into and perform its obligations under this Agreement; (c) it has duly authorized the entry into and performance of its obligations under this Agreement by all requisite corporate actions; (d) when executed by each of the Parties hereto, this Agreement shall be a legal, valid and binding obligation of such party enforceable in accordance with its terms, subject to bankruptcy, insolvency and similar laws affecting creditors' rights generally and general principles of equity; (e) its execution and delivery and performance of its obligations under this Agreement do not breach, violate, conflict with or contravene in any material respect (i) its organizational documents, (ii) any laws, rules, regulations, orders, judgments or decrees applicable to or binding upon it or its property, or (iii) any other agreement, instrument, mortgage, indenture, contract, license or other document to which it is a party or by which it is bound; (f) it has obtained all governmental and third party consents and made all filings and notices required in connection with its execution, delivery and performance of this Agreement, and all such consents, filings and notices remain in full force and effect; and (g) it will comply in all material respects with all applicable laws, rules and regulations in the conduct of its responsibilities and activities under this Agreement. 9.2 ADDITIONAL LIFECELL REPRESENTATIONS AND WARRANTIES. LifeCell represents and warrants to OMP that: -13- (a) all Product will conform in all material respects to the Specifications; (b) LifeCell is and will remain in substantial compliance with good manufacturing practices; (c) LifeCell has, and throughout the Term at all times shall maintain, at LifeCell's sole expense, sufficient right, title and interest in all Intellectual Property (other than the OMP Packaging License and other Intellectual Property owned by OMP) necessary to produce and license the Product for sale in the Territory contemplated by this Agreement; (d) LifeCell holds each item of registered or registrable Intellectual Property (including, without limitation, patents, trademarks, trade names, and applications for any of the foregoing (including the status of such applications and any rejections or challenges thereof)) listed on Exhibit A; (e) there are no interference, opposition or cancellation proceedings pending or threatened against any of the Intellectual Property listed on Exhibit A; (f) no claim, suit or action to which LifeCell is a party or which is known to LifeCell is pending or, to LifeCell's knowledge after due inquiry, threatened alleging that any Product is infringing or would infringe upon the Intellectual Property rights of others; and (g) the Product and the licenses and rights granted or purported to be granted to OMP pursuant to this Agreement with respect thereto do not infringe, violate or otherwise impair any Intellectual Property right or any other proprietary right of any third party in the United States. 9.3 ADDITIONAL OMP REPRESENTATIONS AND WARRANTIES. OMP represents and warrants to LifeCell that: (a) the OMP Packaging License includes all the Intellectual Property rights necessary for LifeCell to produce the packaging and labeling required by this Agreement; (b) it will store, handle and transport the Products, and prepare, maintain and retain all records regarding such matters and its distribution of Product in accordance with (i) all applicable legal requirements then in effect, including without limitation, the regulations of the FDA and the United States Department of Health and Human Services (21 C.F.R. Part 1270), (ii) the Guidelines of the American Association of Tissue Banks and (iii) the specifications and procedures set forth on Exhibit E annexed hereto and incorporated herein, as such exhibit may be revised from time to time upon mutual agreement of the Parties and in compliance with appropriate state statutes and regulations. 9.4 DISCLAIMER OF DAMAGES. WITH THE EXCEPTION OF THE INDEMNIFICATION OBLIGATIONS SET FORTH IN ARTICLE X, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR ANY SPECIAL, COLLATERAL, INDIRECT, EXEMPLARY, INCIDENTAL OR CONSEQUENTIAL -14- DAMAGES, INCLUDING BUT NOT LIMITED TO, LOSS OF GOODWILL, LOSS OF PROFITS, OR LOSS OF USE, FOR BREACH OF ANY OF THE PROVISIONS OF THIS AGREEMENT, REGARDLESS OF WHETHER SUCH LIABILITY IS BASED ON BREACH OF CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, AND EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. X. INDEMNIFICATION 10.1 SCOPE OF INDEMNITY. Each party (the "Indemnifying Party") agrees to indemnify, defend and hold the other party and any of its parent companies and Affiliates, and the present and former officers, members, shareholders, directors, employees, representatives, attorneys, insurers and agents of any of these, and their successors, heirs and assigns (each, an "Indemnified Party") harmless from and against any and all losses, liabilities, claims, costs, damages and expenses (including, without limitation, fines, forfeitures, attorneys' fees, disbursements and administrative or court costs) arising directly or indirectly out of any breach or alleged breach of its representations and warranties in this Agreement. Each party further agrees to indemnify defend and hold the other party, its parent, subsidiaries and affiliates, and each of their respective present and former officers, members, shareholders, directors, employees, representatives, attorneys, agents, successors heirs and assigns (each, an "Indemnified Party"), harmless from any and all losses, liabilities, claims, costs, damages and expenses (including, without limitation, fines, forfeitures, attorneys' fees, disbursements and administrative or court costs) arising directly or indirectly out of (a) the handling or sale of the Product by the Indemnifying Party and (b) the manufacture of the Product by the Indemnifying Party. LifeCell further agrees to indemnify defend and hold OMP, its parent, subsidiaries and affiliates, and each of their respective present and former officers, members, shareholders, directors, employees, representatives, attorneys, agents, successors heirs and assigns (each, an "Indemnified Party"), harmless from any and all losses, liabilities, claims, costs, damages and expenses (including, without limitation, fines, forfeitures, attorneys' fees, disbursements and administrative or court costs) arising directly or indirectly out of the use of the Product by third parties, other than those that arise out of OMP's breach of its obligations under Section 3.7 of this Agreement or any material misprepresentation relating to any Product made by OMP. 10.2 PROCESS. Any Indemnified Party seeking indemnification shall notify the Indemnifying Party of the indemnified claim or action in writing within a reasonably prompt time. Upon receipt of notice of the assertion of a claim, the Indemnifying Party shall employ counsel reasonably acceptable to the Indemnified Party and shall assume defense of the claim. The Indemnified Party shall have the right to employ separate counsel and to participate in (but not control) any such defense. The fees and expenses of such separate counsel shall be at the expense of the Indemnified Party unless (a) the Indemnified Party has been given a formal opinion by its counsel that there is a conflict of interest between it and the Indemnifying Party, or (b) the Indemnifying Party has not in fact employed counsel to assume defense of the action within a reasonable time following receipt of the notice given pursuant to this Agreement, in each of which cases the fees and expenses of such counsel shall be at the expense of the Indemnifying Party. The Indemnifying Party agrees that it will not consent to the entry of any judgment or enter into any settlement which does not include as an unconditional term thereof -15- the giving by the claimant or plaintiff to the Indemnified Party a release from all liability with respect to the claim. Each Indemnified Party shall reasonably cooperate in the defense of any claim for which indemnification is required and shall furnish such records, information, testimony and attend such conferences, discovery proceedings, hearings, trials and appeal as may reasonably requested by the Indemnifying Party. 10.3 IP INFRINGEMENT. If any claim involving infringement, violation or impairment of any kind of Intellectual Property for which LifeCell is obligated to indemnify OMP pursuant to this Article X is resolved in a manner that precludes LifeCell from granting any right included in the Intellectual Property, LifeCell will, at LifeCell's expense: (a) procure such license as is necessary for OMP's past rights and future rights to continue to exercise all rights granted with respect to the Product under this Agreement; (b) replace or modify the allegedly infringing item(s) to avoid the infringement, without materially impairing performance or compliance with the Product's specifications to OMP's reasonable satisfaction, or (c) if neither the procuring of such a license nor the replacement or modification as above-described are economically practicable, accept return of all the Product delivered to OMP which have not been sold to customers and refund OMP all its necessary and reasonable costs incurred as a result of LifeCell's inability to procure the past rights for OMP to continue to exercise all rights granted herein. 10.4 RIGHT TO SET-OFF. Each Indemnified Party shall be entitled to offset against any obligations owed by such party to the Indemnifying Party the sum of all Indemnifiable Damages that such Indemnified Party is entitled to pursuant to this Article X. 10.5 INSURANCE. Each party shall maintain at its expense commercial general liability insurance in a principal amount of not less than the coverage generally maintained by companies of similar size in its industry. Each party shall also maintain a product liability policy relating to any use of the Product at any time after the date of this Agreement with coverage of not less than [***] Dollars ($[***]) per occurrence and [***] Dollars ($[***]) in the aggregate. Each of the policies required under this Section 10.5 and maintained by any party shall name the other party as an additional insured and require the insurer to provide at least thirty (30) days written notice to such other party before any cancellation or material change to the limits, deductibles or terms of such policies. Within thirty (30) days after the date of this Agreement, each party shall furnish to the other party certificates evidencing its insurance, such other party's designation as additional insured, and such notice requirement. Any party may elect to suspend its performance under this Agreement until any insurance required to be maintained by the other party is in place and such certificates of coverage are provided. -16- [***] Material has been omitted pursuant to a request for confidential treatment and such material has been filed separately with the Securities and Exchange Commission. XI. CONFIDENTIAL INFORMATION 11.1 CONFIDENTIAL INFORMATION. Each party acknowledges that it and its employees or agents may, in the course of this Agreement, be exposed to or acquire information which is proprietary or confidential to the other party ("Confidential Information"). Confidential Information hereunder shall include, if disclosed orally and such disclosure contains an oral statement that the information being disclosed is confidential or proprietary (provided such statement is followed by a writing delivered to the receiving party within thirty (30) days of the initial disclosure which indicates the date of disclosure and a non-confidential description of the Confidential Information disclosed, or if disclosed in writing or visually, a legend or some other clear written indication that the information disclosed is confidential or proprietary: (a) marketing, sales, financial, scientific, and other non-public and/or proprietary information concerning the Product, projects, business and operations of such party and its Affiliates including the manufacture, use, or sale of the Product; (b) any technical information, design, process, procedure, formula, improvement, and other data relating to the development or production of the Product; and (c) the terms and conditions of this Agreement. Confidential Information shall not include any information that is: (a) generally known or available to the public through no act of the receiving party, (b) already known to the receiving party at the time of receiving the Confidential Information, or (c) furnished to the receiving party by a third party with the right to do so. In the event that any disclosure of Confidential Information is required by a governmental authority or by order of a court of competent jurisdiction, the disclosing party shall, prior to disclosure and as soon as practicable by the best available means, notify the other party thereof in an effort to permit the disclosing party adequate opportunity to object to the disclosure order or take other action to preserve the confidentiality of the Confidential Information. 11.2 NO ADDITIONAL RIGHTS. The furnishing of Confidential Information by one party to the other shall not constitute any grant, option or license to the other under any patent or other rights now or hereafter held by the furnishing party. 11.3 LENGTH OF SURVIVAL. The provisions of this Article XI shall survive termination of this Agreement and continue for a period of three (3) years. XII. PRODUCT RECALLS; COMPLAINTS AND REGULATORY NOTICES 12.1 RESPONSIBILITY FOR RECALL. In the event any Product must be recalled from the channel of distribution by reason of failure to meet any requirements of law or otherwise, OMP shall have the sole responsibility to effect the recall. LifeCell shall use its best efforts to cooperate with OMP in implementing any such recalls to the extent such cooperation is necessary to effect the recall. 12.2 RESPONSIBILITY FOR REIMBURSEMENT. In the event the recall results from or is caused by an act or omission by OMP, OMP shall reimburse LifeCell for any costs and/or expenses reasonably expended by LifeCell as a consequence of the recall. Without limiting the general nature of the foregoing, OMP shall bear the cost of any Product involved in such recall. In the event the recall results from or is caused by an act or omission by LifeCell, LifeCell shall -17- reimburse OMP for any costs and/or expenses reasonably expended by OMP as a consequence of the recall. Without limiting the general nature of the foregoing, LifeCell will provide replacement Product for recalled Product and for any Product that cannot be shipped due to the condition requiring the recall. XIII. TERM; RENEWAL; TERMINATION 13.1 TERM. This Agreement shall become effective on the Effective Date and shall continue for a period of five (5) years (the "Initial Term"), unless this Agreement is otherwise (a) terminated as provided in this Agreement, or (b) extended by mutual agreement of the Parties in a written instrument executed in conformance with the procedure for amending this Agreement. If OMP meets or exceeds the minimum sales levels described in Section 4.1, or alternatively, makes the payments to LifeCell described in Section 4.2 in a timely manner, and is not otherwise in default of its obligations hereunder, then OMP shall have the right to renew the Agreement for an additional five (5) year term (a "Renewal Term") by notifying LifeCell of its intent to renew the Agreement, in writing, at least one hundred and eighty (180) days prior to the expiration of the Initial Term, in which case the Minimum Annual Sales Amounts set forth in Article IV shall be increased by [***] percent ([***]%) annually for the Term. The Initial Term, any mutually agreed upon extensions, and the Renewal Term(s), if any, shall constitute the "Term" of this Agreement. 13.2 TERMINATION FOR CAUSE. Either party has the right, but not the obligation, to terminate this Agreement in the event of a material breach of this Agreement by the other party, unless such breach is cured within thirty (30) days of receipt of written notice of such breach. 13.3 TERMINATION DUE TO INSOLVENCY OR BANKRUPTCY. Either party may terminate this Agreement upon thirty (30) days advance notice if the other party is declared insolvent or bankrupt by a court of competent jurisdiction, or a voluntary petition of bankruptcy is filed in any court of competent jurisdiction by such party, or such party makes or executes an assignment for the benefit of creditors. 13.4 EVENTS UPON TERMINATION. Upon the termination, expiration or cancellation of this Agreement, all rights granted by LifeCell to OMP with respect to the Product or Improvement shall cease, other than the right to complete the sale of Product then lawfully in its possession. Each party will remain obligated to pay outstanding amounts due prior to the date of termination. Each party will promptly return to the other party or destroy all copies of any Confidential Information, including all notes, abstracts, and other documents that contain Confidential Information, and will provide to the other party a written certification from an officer certifying how such Confidential Information was disposed. The OMP Packaging License and the LifeCell Mark License shall expire upon the expiration, termination or cancellation of this Agreement. 13.5 SURVIVAL OF TERMINATION. The obligations of the parties under Articles I, IX, X, XI, XIV and XV shall survive any such expiration, termination or cancellation, subject to any limitation specified in such Article and Section. -18- [***] Material has been omitted pursuant to a request for confidential treatment and such material has been filed separately with the Securities and Exchange Commission. XIV. ALTERNATIVE DISPUTE RESOLUTION 14.1 DISPUTE RESOLUTION. In order to attempt to resolve any dispute between the Parties hereunder, and except as otherwise specifically provided herein to the contrary, as a condition precedent to the non-breaching party terminating this Agreement under Section 13.2 or as otherwise provided in this Agreement, or filing a suit, instituting a proceeding or seeking other governmental resolution in connection with this Agreement, the Parties, with the help and assistance of the Joint Management Committee, will attempt to reach a mutually agreeable resolution of the dispute through best efforts negotiation for a minimum of thirty (30) business days. If the Parties are unable to reach a mutually agreeable resolution within such thirty (30) business days, then the Parties shall submit the dispute to a non-binding mediation for a minimum of an additional sixty (60) business days, utilizing a single mediator who is a retired judge mutually agreed upon by the Parties. If the Parties are unable to reach a mutually agreeable resolution within such ninety (90) business days, either party may exercise its rights hereunder in the manner selected by such party in order to resolve the dispute. XV. MISCELLANEOUS 15.1 PREAMBLE; RECITALS. The Preamble and Recitals set forth above are intended to be an integral part of this Agreement, and the Preamble and Recitals (including the definitions set forth therein) are hereby incorporated by reference. 15.2 NOTICES. Any notices required or permitted to be given hereunder shall be delivered by personal delivery, overnight commercial courier or by certified mail, return receipt requested, at the address of the parties specified below, and shall be effective upon receipt. Either party may at any time designate another person or address for the receipt of notice by notifying the other party in accordance with this Section 15.2. If to LifeCell: If to OMP: LifeCell Obagi Medical Products, Inc. One Millenium Way 310 Golden Shore Branchburg, NJ 08876 Long Beach, CA 90802 Attn: Paul Thomas, CEO Attn: Philip Rose -19- With a copy to: Lowenstein Sandler, PC Michael Best & Friedrich LLP 50 Division Street One South Pinckney St, #700 Somerville, NJ 08876 Madison, WI 53703 Attn: Steven B. Fuerst, Esq. Attn: Tod B. Linstroth, Esq. 15.3 FORCE MAJEURE. Neither party shall be deemed in default or otherwise liable under this Agreement due to its inability to perform its obligations by reason of any fire, earthquake, flood, substantial snowstorm, epidemic, accident, explosion, casualty, strike, lockout, labor controversy, riot, civil disturbance, act of public enemy, embargo, war, act of God, or any municipal, county, state or national ordinance or law, or any executive, administrative or judicial order (which order is not the result of any act or omission which would constitute a default hereunder), or any failure or delay of any transportation, power, or communications system or any other or similar cause beyond that party's reasonable control. 15.4 GOVERNING LAW. This Agreement and all matters or issues related this Agreement shall be governed by the laws of the State of New Jersey without regard to its choice of law or conflict of laws rules. 15.5 ASSIGNMENT. Neither party shall sell, assign, mortgage or otherwise transfer any of its rights or obligations under this Agreement without the consent of the other party, such consent not to be unreasonably withheld, conditioned or delayed, nor shall any of said rights or obligations be assigned or transferred by operation of law or otherwise without such consent. Notwithstanding the foregoing, either party may assign this Agreement in connection with a sale of all or substantially all of its assets or equity interests, or to any Affiliate. In the event of any permitted assignment or transfer, the approved assignee shall agree to accept and abide by all of the terms and conditions of this Agreement. 15.6 RELATIONSHIP OF PARTIES: NO JOINT VENTURE. Neither this Agreement nor the cooperation of the parties contemplated under this Agreement shall be deemed or construed to create any partnership, joint venture or other business entity between OMP and LifeCell. 15.7 SEVERABILITY. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement. In the event that any provision of this Agreement is determined to be invalid, unenforceable or otherwise illegal, such provision shall be deemed restated, in accordance with applicable law, to reflect as nearly as possible the original intentions of the parties, and the remainder of this Agreement shall remain in full force and effect. 15.8 WAIVER. No term or condition of this Agreement shall be deemed waived, and no breach shall be deemed excused, unless such waiver or excuse is in writing and is executed by the party against whom such waiver or excuse is claimed. -20- 15.9 ENTIRE AGREEMENT; AMENDMENTS. This Agreement, including all Exhibits, contains the entire agreement and understanding between the parties with regard to the subject matter hereof, and supersedes all prior and contemporaneous oral or written agreements and representations. Any amendment of this Agreement shall be in writing and signed by both parties. 15.10 COMMUNICATIONS. Each party agrees that it shall not make any public announcement regarding the cooperative relationship described in this Agreement without the prior approval of the other, both as to timing and substance, such approval not to be unreasonably withheld. 15.11 COUNTERPARTS. This Agreement may be executed in one or more counterparts, each of which shall constitute an original and all of which taken together shall constitute one and the same Agreement. -21- IN WITNESS WHEREOF, the parties, intending to be legally bound, as described in the Preamble, have caused this Agreement to be executed by their authorized representatives. LifeCell Corporation Obagi Medical Products, Inc. By: /s/ P. Thomas By: /s/ Phillip Rose -------------------------------- ------------------------------- Name: Paul G. Thomas Name: Phillip J. Rose ------------------------------ ----------------------------- Title: President & CEO Title: President & CEO ----------------------------- ---------------------------- -23- EXHIBIT A SCHEDULE OF INTELLECTUAL PROPERTY OWNED BY LIFECELL U.S. Patent No. 5,336,616 "Method for Processing and Preserving Collagen-Based Tissues for Transplantation" Corresponding Applications filed or issued: AU, CA, EP, JP U.S. Application No. 08/759,801 "Method for Processing and Preserving Collagen-Based Tissues for Transplantation" U.S. Application No. 09/207,179 "Reconstituted Skin" PCT Application No. US99/038667 "Method for Processing and Preserving Collagen-Based Tissues" PCT Application No. US99/13861 "Particulate Acellular Tissue Matrix" (Micronized ALLODERM-Registered Trademark-) TRADEMARK PORTFOLIO LIFECELL-Registered Trademark- Registration No. 1,475,428 ALLODERM-Registered Trademark- Registration No. 1,782,561 TRADEMARK PORTFOLIO UNDER CONSIDERATION MICRONIZED ALLODERM-TM- CYMETRA-TM- A-1 EXHIBIT B - -------------------------------------------------------------------------------- LIFECELL CORPORATION, THE WOODLANDS, TEXAS FINISHED GOOD SPECIFICATION 100A0008 MICRONIZED ALLODERM, 330 MG VIAL Rev. A LifeCell Part No.: 602001 Page 1 of 2 - -------------------------------------------------------------------------------- 1 PURPOSE This specification describes the required characteristics of Micronized AlloDerm, requirements for raw materials, and, by reference, the process required to produce, inspect, ship, and track individual pieces to the customer. 2 APPLICABLE DOCUMENTS The following documents are referenced in this specification by title: AATB, STANDARDS FOR TISSUE BANKING FDA INTERIM RULE, CFR 1270 2.1 Design Documents 111A0001 SKIN, HUMAN, CADAVER 2.2 Manufacturing Documents 002S0014 PACKAGING FOR MICRONIZED ALLODERM 100S0008 MICRONIZED ALLODERM 2.3 Quality Assurance Documents 001S0002 ALLODERM TRACKING 001S0054 QA RELEASE FOR MICRONIZED ALLODERM 3 DESCRIPTION Micronized AlloDerm is a freeze-dried acellular matrix derived from papillary and reticular human dermis and is characterized by the following: a Dermal and epidermal cells removed, evidenced by histological analysis b Collagen bundles are intact, evidenced by electron microscopic analysis c Absence of commensal and pathogenic microorganisms per microbiological testing (method CFR 610.12/Viromed or equivalent) d Macroscopic appearance should be white to buff-colored and not exhibit consolidated aggregates that cannot be broken up when the dry sample is agitated e Residual moisture content of LESS THAN OR EQUAL TO 5%, evidenced by residual moisture analysis 4 QUALITY ASSURANCE 4.1 TESTING All tissue processed for Micronized AlloDerm shall be tested and accepted/rejected per QA Release for Micronized AlloDerm (001S0054). 4.2 TRACKING Micronized AlloDerm supplied by LifeCell for transplantation or testing shall be tracked per AlloDerm Tracking in accordance with FDA Interim Rule CFR 1270. Page 2 of 2 5 PACKAGING/LABELING 5.1 PACKAGING Each dose of Micronized AlloDerm shall be packaged in an autoclaved siliconized glass vial with a minimum of 330 mg of dry product per dose. 5.2 LABELING All package labels (excluding marketing overlabels) shall be capable of withstanding temperatures of -35DEG.C to +40DEG.C without adverse effects on the printing or loss of label adhesion to the vials. 6 STORAGE All Micronized AlloDerm which meets the requirements of the QA Release for Micronized AlloDerm, and is hence accepted for Finished Goods, shall be stored in a restricted, temperature-controlled environment (1DEG.C to 10DEG.C) until the time of distribution. All Micronized AlloDerm, which does not meet the requirements, and is hence rejected, shall be stored in a separate temperature-controlled environment until such time that the disposition of such tissue is determined. FINAL OBAGI CUSTOMER LIST 2/9/00 EXHIBIT C
- ------------------------------------------------------------------------------------------------------------------------------------ TNX CUST SUM OF O # CUST ID YR TYPE PECIA TER TNXAMT NAME ADDRESS CITY STATE ZIP VS L - ------------------------------------------------------------------------------------------------------------------------------------ 1 4528 99 O PL 101 $ [***] O 2 3689 99 O PL 101 $ O 3 4729 99 O PL 101 $ O 4 4391 99 O PL 101 $ O 5 4298 99 O PL 101 $ O 6 4043 99 O PL 101 $ O 7 4543 99 O PL 101 $ O 8 3832 99 O PL 101 $ O 9 4403 99 O PL 101 $ O 10 3957 99 O PL 101 $ O 11 4397 99 O PL 101 $ O 12 4233 99 O PL 101 $ O 13 3140 99 O PL 101 $ O 14 1387 99 O PL 101 $ O 15 3379 99 O PL 101 $ O 16 4579 99 O PL 101 $ O 17 3218 99 O PL 101 $ O 18 3347 99 O PL 101 $ O 19 3052 99 O PL 101 $ O 20 3245 99 O PL 101 $ O 21 4639 99 O PL 101 $ O 22 4000 99 O PL 101 $ O 23 3599 99 O PL 101 $ O 24 3165 99 O PL 101 $ O 25 3706 99 O PL 101 $ O 26 4395 99 O PL 101 $ O 27 3973 99 O PL 101 $ O 28 3902 99 O PL 101 $ O 29 4488 99 O PL 101 $ O 30 3870 99 O PL 101 $ O 31 4324 99 O PL 101 $ O 32 3161 99 O PL 102 $ O 33 4779 00 O PL 102 O 34 4011 99 O PL 102 $ O 35 4793 00 O PL 102 O 36 3110 99 O PL 102 $ O 37 3617 99 O PL 102 $ O 38 4836 00 O PL 102 O 39 3146 99 O PL 102 $ O 40 4792 00 O PL 103 O 41 2510 99 O PL 103 $ O
*** Material has been omitted pursuant to a request for confidential treatment and such material has been filed separately with the Securities and Exchange Commission. FINAL OBAGI CUSTOMER LIST 2/9/00 EXHIBIT C
- ------------------------------------------------------------------------------------------------------------------------------------ TAX CUST SUM OF O # CUST ID YR TYPE PECIA TER TAX AMT NAME ADDRESS CITY STATE ZIP VS L - ------------------------------------------------------------------------------------------------------------------------------------ 42 3732 99 O PL 103 $ [***] [***] 0 43 3564 99 O PL 104 $ 0 44 3964 99 O PL 104 $ 0 45 2951 99 O PL 104 $ 0 46 4037 99 O PL 104 $ 0 47 4612 99 O PL 104 $ 0 48 3448 99 O PL 104 $ 0 49 4451 99 O PL 104 $ 0 50 4565 99 O PL 104 $ 0 51 3071 99 O PL 104 $ 0 52 4578 99 O PL 104 $ 0 53 2889 99 O PL 104 $ 0 54 4704 99 O PL 105 $ 0 55 4359 99 O PL 105 $ 0 56 3049 99 O PL 105 $ 0 57 4004 99 O PL 105 $ 0 58 3655 99 O PL 105 $ 0 59 4439 99 O PL 105 $ 0 60 4036 99 O PL 105 $ 0 61 4412 99 O PL 105 $ 0 62 4056 99 O PL 105 $ 0 63 1413 99 O PL 105 $ 0 64 4722 99 O PL 105 $ 0 65 2556 99 O PL 105 $ 0 66 3887 99 O PL 105 $ 0 67 4159 99 O PL 105 $ 0 68 2962 99 O PL 105 $ 0 69 4082 99 O PL 105 $ 0 70 2887 99 O PL 105 $ 0 71 4363 99 O PL 105 $ 0 72 1467 99 O PL 105 $ 0 73 3639 99 O PL 105 $ 0 74 4060 99 O PL 105 $ 0 75 4156 99 O PL 105 $ 0 76 4510 99 O PL 105 $ 0 77 2936 99 O PL 105 $ 0 78 4350 99 O PL 105 $ 0 79 3770 99 O PL 105 $ 0 80 4126 99 O PL 106 $ 0 81 3882 99 O PL 106 $ 0 82 2968 99 O PL 107 $ 0
[***] Material has been omitted pursuant to a request for confidential treatment and such material has been filed separately with the Securities and Exchange Commission.
- ------------------------------------------------------------------------------------------------------------------------------------ TAX CUST SUM OF O # CUST ID YR TYPE PECIA TER TAX AMT NAME ADDRESS CITY STATE ZIP VS L - ------------------------------------------------------------------------------------------------------------------------------------ 83 4854 99 O PL 107 $ [***] [***] 0 84 4549 99 O PL 107 $ 0 85 2623 99 O PL 108 $ 0 86 2882 99 O PL 108 $ 0 87 4311 99 O PL 108 $ 0 88 2988 99 O PL 108 $ 0 89 3585 99 O PL 108 $ 0 90 4725 99 O PL 108 $ 0 91 4758 99 O PL 108 $ 0 92 2997 99 O PL 108 $ 0 93 3357 99 O PL 108 $ 0 94 2009 99 O PL 108 $ 0 95 1341 99 O PL 108 $ 0 96 4422 99 O PL 108 $ 0 97 4585 99 O PL 108 $ 0 98 2910 99 O PL 108 $ 0 99 3002 99 O PL 108 $ 0 100 4306 99 O PL 108 $ 0 101 3802 99 O PL 108 $ 0 102 3394 99 O PL 108 $ 0 103 3374 99 O PL 108 $ 0 104 3145 99 O PL 108 $ 0 105 4356 99 O PL 108 $ 0 106 4194 99 O PL 108 $ 0 107 4234 99 O PL 109 $ 0 108 3124 99 O PL 109 $ 0 109 4512 99 O PL 109 $ 0 110 3662 99 O PL 109 $ 0 111 3851 99 O PL 109 $ 0 112 4824 99 O PL 109 $ 0 113 3927 99 O PL 109 $ 0 114 4376 99 O PL 109 $ 0 115 4053 99 O PL 109 $ 0 116 4844 00 O PL 109 $ 0 117 3122 99 O PL 109 $ 0 118 1323 99 O PL 109 $ 0 119 4244 99 O PL 109 $ 0 120 4114 99 O PL 109 $ 0 121 3073 99 O PL 109 $ 0 122 4751 99 O PL 109 $ 0 123 4149 99 O PL 109 $ 0
*** Material has been omitted pursuant to a request for confidential treatment and such material has been filed separately with the Securities and Exchange Commission.
FINAL OBAGI CUSTOMER LIST 2/9/00 EXHIBIT C - ------------------------------------------------------------------------------------------------------------------------------------ TNX CUST SUM OF O # CUST ID YR TYPE SPECIALTY TER TNXAMT NAME ADDRESS CITY STATE ZIP VSL - ------------------------------------------------------------------------------------------------------------------------------------ 124 3749 99 O PL 109 $ [***] 0 125 4353 99 O PL 109 $ 0 126 4643 99 O PL 109 $ 0 127 3322 99 O PL 109 $ 0 128 3612 99 O PL 109 $ 0 129 4217 99 O PL 109 $ 0 130 4220 99 O PL 109 $ 0 131 3536 99 O PL 109 $ 0 132 3813 99 O PL 109 $ 0 133 3949 99 O PL 109 $ 0 134 3074 99 O PL 109 $ 0 135 3586 99 O PL 202 $ 0 136 3842 99 O PL 202 $ 0 137 3605 99 O PL 202 $ 0 138 4765 99 O PL 202 0 139 4717 99 O PL 202 $ 0 140 4317 99 O PL 202 $ 0 141 4463 99 O PL 202 $ 0 142 3886 99 O PL 202 $ 0 143 4461 99 O PL 202 $ 0 144 4185 99 O PL 202 $ 0 145 3562 99 O PL 202 $ 0 146 4572 99 O PL 202 $ 0 147 4161 99 O PL 202 $ 0 148 4335 99 O PL 202 $ 0 149 3632 99 O PL 202 $ 0 150 4640 99 O PL 202 $ 0 151 3669 99 O PL 202 $ 0 152 4111 99 O PL 202 $ 0 153 3481 99 O PL 202 $ 0 154 4470 99 O PL 202 $ 0 155 3567 99 O PL 202 $ 0 156 3327 99 O PL 202 $ 0 157 4088 99 O PL 202 $ 0 158 3998 99 O PL 202 $ 0 159 3890 99 O DM 202 $ 0 160 4044 99 O PL 202 $ 0 161 4731 99 O PL 202 $ 0 162 3987 99 O PL 204 $ 0 163 4448 99 O PL 204 $ 0 164 3602 99 O PL 204 $ 0
[***] Material has been omitted pursuant to a request for confidential treatment and such material has been filed separately with the Securities and Exchange Commission.
FINAL OBAGI CUSTOMER LIST 2/9/00 EXHIBIT C - ------------------------------------------------------------------------------------------------------------------------------------ TNX CUST SUM OF O # CUST ID YR TYPE SPECIALTY TER TNXAMT NAME ADDRESS CITY STATE ZIP VSL - ------------------------------------------------------------------------------------------------------------------------------------ 165 3516 99 O PL 204 $ [***] 0 166 3845 99 O PL 204 $ 0 167 4216 99 O PL 204 $ 0 168 4007 99 O PL 204 $ 0 169 4592 99 O PL 204 $ 0 170 4485 99 O PL 204 $ 0 171 3954 99 O PL 204 $ 0 172 4224 99 O PL 204 $ 0 173 3556 99 O PL 204 $ 0 174 4521 99 O PL 204 $ 0 175 4638 99 O PL 204 $ 0 176 3788 99 O PL 204 $ 0 177 3500 99 O PL 204 $ 0 178 3804 99 O PL 204 $ 0 179 4806 00 O PL 204 0 180 4519 99 O PL 204 $ 0 181 3900 99 O PL 204 $ 0 182 3691 99 O PL 204 $ 0 183 3779 99 O PL 204 $ 0 184 3103 99 O PL 204 $ 0 185 4603 00 O PL 204 0 186 3750 99 O PL 204 $ 0 187 3597 99 O PL 204 $ 0 188 3953 99 O PL 204 $ 0 189 4573 99 O PL 204 $ 0 190 4827 00 O PL 204 0 191 4084 99 O PL 204 $ 0 192 3961 99 O PL 204 $ 0 193 4398 99 O PL 206 $ 0 194 4257 99 O PL 206 $ 0 195 3422 99 O PL 206 $ 0 196 3211 99 O PL 206 $ 0 197 3554 99 O PL 206 $ 0 198 9999 00 O PL 206 0 199 4249 99 O PL 206 $ 0 ###-###-#### 99 O PL 206 $ 0 ###-###-#### 99 O PL 206 $ 0 ###-###-#### 99 O PL 206 $ 0
[***] Material has been omitted pursuant to a request for confidential treatment and such material has been filed separately with the Securities and Exchange Commission. FINAL OBAGI CUSTOMER LIST 2/9/00 EXHIBIT C
- ------------------------------------------------------------------------------------------------------------------------------------ TAX CUST SUM OF O # CUST ID YR TYPE PECIA TER TAX AMT NAME ADDRESS CITY STATE ZIP VS L - ------------------------------------------------------------------------------------------------------------------------------------ 203 2891 99 O PL 206 $ [***] [***] 0 ###-###-#### 00 O PL 206 0 ###-###-#### 99 O PL 206 $ 0 ###-###-#### 99 O PL 206 $ 0 ###-###-#### 99 O PL 206 $ 0 ###-###-#### 99 O PL 207 $ 0 ###-###-#### 99 O PL 207 $ 0 ###-###-#### 00 O PL 207 0 211 1206 99 O PL 207 $ 0 ###-###-#### 99 O PL 207 $ 0 ###-###-#### 99 O PL 207 $ 0 ###-###-#### 00 O PL 207 0 ###-###-#### 00 O PL 207 0 ###-###-#### 99 O PL 207 $ 0 ###-###-#### 00 O PL 207 0 ###-###-#### 99 O PL 207 $ 0 ###-###-#### 00 O PL 208 0 ###-###-#### 99 O PL 208 $ 0 ###-###-#### 99 O PL 208 $ 0 ###-###-#### 99 O PL 208 $ 0 ###-###-#### 99 O PL 208 $ 0 ###-###-#### O PL 209 0 ###-###-#### 99 O PL 209 $ 0 ###-###-#### 99 O PL 209 $ 0 ###-###-#### 99 O PL 209 $ 0 ###-###-#### O PL 209 0 ###-###-#### 99 O PL 210 $ 0 ###-###-#### 99 O PL 210 $ 0 ###-###-#### 99 O PL 210 $ 0 ###-###-#### 99 O PL 211 $ 0 ###-###-#### 99 O PL 211 $ 0 ###-###-#### 99 O PL 211 $ 0 ###-###-#### 99 O PL 211 $ 0 ###-###-#### 00 O PL 211 0 ###-###-#### 99 O PL 211 $ 0 ###-###-#### 99 O PL 211 $ 0 ###-###-#### 99 O PL 211 $ 0 ###-###-#### 99 O PL 211 $ 0 ###-###-#### 99 O PL 211 $ 0 ###-###-#### 99 O PL 211 $ 0 ###-###-#### 99 O PL 211 $ 0 - ----------------------------------------------------------------------------------------------------------------------------------
[***] Material has been omitted pursuant to a request for confidential treatment and such material has been filed separately with the Securities and Exchange Commission. FINAL OBAGI CUSTOMER LIST 2/9/00 EXHIBIT C
- ------------------------------------------------------------------------------------------------------------------------------------ TAX CUST SUM OF O # CUST ID YR TYPE PECIA TER TAX AMT NAME ADDRESS CITY STATE ZIP VS L - ------------------------------------------------------------------------------------------------------------------------------------ 244 3336 99 O PL 211 $ [***] [***] 0 ###-###-#### 99 O PL 211 $ 0 ###-###-#### 99 O PL 211 $ 0 ###-###-#### 99 O PL 211 $ 0 ###-###-#### 99 O PL 211 0 ###-###-#### 99 O PL 401 0 ###-###-#### 99 O PL 401 $ 0 ###-###-#### 99 O PL 401 $ 0 ###-###-#### 99 O PL 401 $ 0 ###-###-#### 99 O PL 401 $ 0 ###-###-#### 99 O PL 401 $ 0 ###-###-#### 99 O PL 401 $ 0 ###-###-#### 99 O PL 401 $ 0 ###-###-#### 99 O PL 401 $ 0 ###-###-#### 99 O PL 401 $ 0 ###-###-#### 99 O PL 401 $ 0 ###-###-#### 99 O PL 401 $ 0 ###-###-#### 99 O PL 401 $ 0 ###-###-#### 99 O PL 401 $ 0 ###-###-#### 99 O PL 401 $ 0 ###-###-#### 99 O PL 401 $ 0 ###-###-#### 99 O PL 401 $ 0 ###-###-#### 99 O PL 401 $ 0 ###-###-#### 99 O PL 401 $ 0 ###-###-#### 99 O PL 401 $ 0 ###-###-#### 99 O PL 401 $ 0 ###-###-#### 00 O PL 401 0 ###-###-#### 99 O PL 401 $ 0 ###-###-#### 99 O PL 401 $ 0 ###-###-#### 99 O PL 401 $ 0 ###-###-#### 99 O PL 401 $ 0 ###-###-#### 99 O PL 401 $ 0 ###-###-#### 99 O PL 401 $ 0 ###-###-#### 99 O PL 401 $ 0 ###-###-#### 99 O PL 401 $ 0 ###-###-#### 99 O PL 401 $ 0 ###-###-#### OO O PL 401 0 ###-###-#### 99 O PL 401 $ 0 ###-###-#### 99 O PL 401 $ 0 ###-###-#### 99 O PL 401 $ 0 ###-###-#### 99 O PL 401 $ 0 - ----------------------------------------------------------------------------------------------------------------------------------
[***] Material has been omitted pursuant to a request for confidential treatment and such material has been filed separately with the Securities and Exchange Commission. FINAL OBAGI CUSTOMER LIST 2/9/00 EXHIBIT C
- ----------------------------------------------------------------------------------------------------------------------------------- TNX CUST SUM OF O # CUST ID YR TYPE SPECIALTY TER TNXAMT NAME ADDRESS CITY STATE ZIP VS L - ----------------------------------------------------------------------------------------------------------------------------------- 285 3528 99 O PL 401 $ [***] O ###-###-#### 99 O PL 401 $ O ###-###-#### 99 O PL 401 $ O ###-###-#### 99 O PL 401 $ O ###-###-#### 99 O PL 401 $ O ###-###-#### 99 O PL 401 $ O ###-###-#### 00 O PL 404 $ O ###-###-#### 99 O PL 404 $ O ###-###-#### 99 O PL 404 $ O ###-###-#### 99 O PL 404 $ O ###-###-#### 99 O PL 404 $ O ###-###-#### 99 O PL 404 $ O ###-###-#### 99 O PL 404 $ O ###-###-#### 00 O PL 404 $ O ###-###-#### 99 O PL 404 $ O ###-###-#### 99 O PL 404 $ O ###-###-#### 99 O PL 404 $ O ###-###-#### 99 O PL 404 $ O ###-###-#### 99 O PL 404 $ O ###-###-#### 99 O PL 404 $ O ###-###-#### 99 O PL 404 $ O ###-###-#### 00 O PL 404 $ O ###-###-#### 99 O PL 404 $ O ###-###-#### 99 O PL 404 $ O ###-###-#### 99 O PL 404 $ O ###-###-#### 99 O PL 404 $ O 311 2568 99 O PL 404 $ O ###-###-#### 99 O PL 404 $ O ###-###-#### 99 O PL 404 $ O ###-###-#### 99 O PL 404 $ O ###-###-#### 00 O PL 405 $ O ###-###-#### 99 O PL 405 $ O ###-###-#### 99 O PL 405 $ O ###-###-#### 00 O PL 405 $ O ###-###-#### 99 O PL 405 $ O ###-###-#### 99 O PL 405 $ O ###-###-#### 99 O PL 405 $ O ###-###-#### 00 O PL 405 $ O ###-###-#### 00 O PL 405 $ O ###-###-#### 99 O PL 405 $ O ###-###-#### 99 O PL 405 $ O
[***] Material has been omitted pursuant to a request for confidential treatment and such material has been filed separately with the Securities and Exchange Commission. FINAL OBAGI CUSTOMER LIST 2/9/00 EXHIBIT C
- ----------------------------------------------------------------------------------------------------------------------------------- TNX CUST SUM OF O # CUST ID YR TYPE SPECIALTY TER TNXAMT NAME ADDRESS CITY STATE ZIP VS L - ----------------------------------------------------------------------------------------------------------------------------------- 326 4550 99 O PL 405 $ [***] O ###-###-#### 00 O PL 405 $ O ###-###-#### 99 O PL 405 $ O ###-###-#### 99 O PL 405 $ O ###-###-#### 99 O PL 405 $ O ###-###-#### 99 O PL 406 $ O ###-###-#### 99 O PL 406 $ O ###-###-#### 99 O PL 406 $ O ###-###-#### 99 O PL 406 $ O ###-###-#### 99 O PL 406 $ O ###-###-#### 99 O PL 406 $ O ###-###-#### 99 O PL 406 $ O ###-###-#### 99 O PL 406 $ O ###-###-#### 99 O PL 406 $ O ###-###-#### 00 O PL 406 $ O ###-###-#### 99 O PL 406 $ O ###-###-#### 99 O PL 406 $ O ###-###-#### 99 O PL 406 $ O ###-###-#### 99 O PL 406 $ O ###-###-#### 99 O PL 406 $ O ###-###-#### 99 O PL 406 $ O ###-###-#### 99 O PL 406 $ O ###-###-#### 99 O PL 406 $ O ###-###-#### 99 O PL 406 $ O ###-###-#### 99 O PL 406 $ O ###-###-#### 00 O PL 406 $ O ###-###-#### 99 O PL 406 $ O ###-###-#### 99 O PL 406 $ O ###-###-#### 99 O PL 406 $ O ###-###-#### 99 O PL 406 $ O ###-###-#### 99 O PL 406 $ O ###-###-#### 99 O PL 407 $ O ###-###-#### 99 O PL 407 $ O ###-###-#### 99 O PL 407 $ O ###-###-#### 00 O PL 407 $ O ###-###-#### 99 O PL 407 $ O ###-###-#### 00 O PL 407 $ O ###-###-#### 99 O PL 407 $ O ###-###-#### 99 O PL 407 $ O ###-###-#### 99 O PL 407 $ O ###-###-#### 99 O PL 407 $ O
[***] Material has been omitted pursuant to a request for confidential treatment and such material has been filed separately with the Securities and Exchange Commission. FINAL OBAGI CUSTOMER LIST 2/9/00 EXHIBIT C
# CUST TAX CUST SUM OF O ID YR TYPE OECIA TER TAX AMT NAME ADDRESS CITY STATE ZIP VS L ============================================================================================================================ 367 2953 99 0 PL 407 $ [***] 0 ###-###-#### 99 0 PL 407 $ 0 ###-###-#### 99 0 PL 407 $ 0 ###-###-#### 99 0 PL 407 $ 0 ###-###-#### 99 0 PL 408 $ 0 ###-###-#### 99 0 PL 408 $ 0 ###-###-#### 99 0 PL 408 $ 0 ###-###-#### 99 0 PL 408 $ 0 ###-###-#### 99 0 PL 408 $ 0 ###-###-#### 99 0 PL 408 $ 0 ###-###-#### 99 0 PL 408 $ 0 ###-###-#### 00 0 PL 408 $ 0 ###-###-#### 99 0 PL 408 $ 0 ###-###-#### 99 0 PL 408 $ 0 ###-###-#### 99 0 PL 408 $ 0 ###-###-#### 99 0 PL 408 $ 0 ###-###-#### 99 0 PL 408 $ 0 ###-###-#### 99 0 PL 408 $ 0 ###-###-#### 99 0 PL 408 $ 0 ###-###-#### 99 0 PL 408 $ 0 ###-###-#### 99 0 PL 408 $ 0 ###-###-#### 99 0 PL 408 $ 0 ###-###-#### 00 0 PL 408 $ 0 ###-###-#### 99 0 PL 408 $ 0 ###-###-#### 99 0 PL 408 $ 0 ###-###-#### 99 0 PL 408 $ 0 ###-###-#### 00 0 PL 408 $ 0 ###-###-#### 99 0 PL 408 $ 0 ###-###-#### 99 0 PL 408 $ 0 ###-###-#### 99 0 PL 408 $ 0 ###-###-#### 99 0 PL 408 $ 0 ###-###-#### 99 0 PL 408 $ 0 ###-###-#### 99 0 PL 408 $ 0 ###-###-#### 99 0 PL 408 $ 0 ###-###-#### 99 0 PL 408 $ 0 ###-###-#### 99 0 PL 408 $ 0 ###-###-#### 99 0 PL 408 $ 0 ###-###-#### 99 0 PL 409 $ 0 ###-###-#### 99 0 PL 409 $ 0 ###-###-#### 99 0 PL 409 $ 0 ###-###-#### 99 0 PL 409 $ 0 [***] Material has been omitted pursuant to a request for confidential treatment and such material has been filed separately with the Securities and Exchange Commission. 408 3695 99 0 PL 409 $ [***] 0 ###-###-#### 99 0 PL 409 $ 0 ###-###-#### 99 0 PL 409 $ 0 411 1618 99 0 PL 899 $ 0 ###-###-#### 99 0 PL 899 $ 0 ###-###-#### 99 0 PL 899 $ 0 ###-###-#### 99 0 PL 899 $ 0 ###-###-#### 99 0 PL 899 $ 0 ###-###-#### 99 0 PL 899 $ 0 ###-###-#### 99 0 PL 899 $ 0 ###-###-#### 99 0 PL 899 $ 0 ###-###-#### 99 0 PL 899 $ 0 ###-###-#### 99 0 PL 899 $ 0 ###-###-#### 99 0 PL 899 $ 0 ###-###-#### 99 0 PL 899 $ 0 - ---------------------------------------------------------------------------------------------------------------------------- $ - ---------------------------------------------------------------------------------------------------------------------------- TOTAL ACCOUNTS FOR OBAGI = ============================================================================================================================
[***] Material has been omitted pursuant to a request for confidential treatment and such material has been filed separately with the Securities and Exchange Commission. FINAL LIFECELL CUSTOMER LIST 2/9/2000 EXHIBIT D
- ----------------------------------------------------------------------------------------------------------------------------------- TAX CUST SUM OF O # CUST ID YR TYPE PECIA TER TAX AMT NAME ADDRESS CITY STATE ZIP # VS L - ------------------------------------------------------------------------------------------------------------------------------------ 1 3240 99 O PL 101 $ [***] [***] 9 L 2 3344 99 O PL 101 $ 8 L 3 1332 99 O PL 101 $ 12 L 4 4176 99 O PL 101 $ 5 L 5 3025 99 O PL 101 $ 7 L 6 3834 99 O PL 101 $ 2 L 7 4169 99 O PL 101 $ 1 L 8 3551 99 O PL 101 $ 7 L 9 4221 99 O PL 101 $ 2 L 10 4369 99 O PL 101 $ 1 L 11 3189 99 O PL 101 $ 2 L 12 3726 99 O PL 101 $ 3 L 13 4712 99 O PL 101 $ 2 L 14 4147 99 O PL 101 $ 3 L 15 1565 99 O PL 102 $ 3 L 16 3131 99 O PL 102 $ 8 L 17 3090 99 O PL 102 $ 4 L 18 3016 99 O PL 102 $ 7 L 19 3204 99 O PL 102 $ 7 L 20 3492 99 O PL 102 $ 3 L 21 3138 99 O PL 102 $ 3 L 22 4184 99 O PL 102 $ 1 L 23 4287 99 O PL 102 $ 2 L 24 3057 99 O PL 102 $ 2 L 25 3627 99 O PL 102 $ 2 L 26 1352 99 O PL 102 $ 1 L 27 3754 99 O PL 102 $ 1 L 28 4153 99 O PL 102 $ 1 L 29 4507 99 O PL 102 $ 1 L 30 4515 99 O PL 102 $ 1 L 31 3051 99 O DM 103 $ 6 L 32 4066 99 O PL 103 $ 5 L 33 3202 99 O PL 103 $ 8 L 34 4630 99 O PL 103 $ 1 L 35 4633 99 O PL 103 $ 1 L 36 2518 99 O PL 103 $ 9 L 37 3230 99 O PL 103 $ 3 L 38 4407 99 O PL 103 $ 2 L 39 3401 99 O PL 103 $ 4 L 40 3716 99 O PL 103 $ 3 L 41 2530 99 O PL 103 $ 4 L 42 3857 99 O PL 103 $ 3 L 43 3631 99 O PL 103 $ 1 L 44 4040 99 O PL 103 $ 1 L 45 3212 99 O PL 103 $ 1 L 46 4343 99 O PL 103 $ 1 L 47 3199 99 O PL 103 $ 3 L 48 3427 99 O PL 103 $ 1 L 49 4629 00 O PL 103 $ L 50 2972 99 O PL 104 $ 10 L 51 1515 99 O PL 104 $ 12 L 52 4092 99 O PL 104 $ 4 L 53 3403 99 O PL 104 $ 2 L 54 3535 99 O PL 104 $ 1 L 55 4427 99 O PL 104 $ 3 L 56 4122 99 O PL 104 $ 1 L 57 4495 99 O PL 104 $ 2 L 58 4518 99 O PL 104 $ 1 L 59 4732 99 O PL 104 $ 1 L 60 4275 99 O PL 104 $ 5 L 61 4125 99 O PL 104 $ 2 L 62 3003 99 O PL 104 $ 3 L 63 2487 99 O PL 104 $ 1 L 64 3630 99 O PL 104 $ 1 L 65 1375 99 O PL 105 $ 7 L 66 3066 99 O PL 105 $ 12 L 67 2919 99 O PL 105 $ 8 L 68 3180 99 O PL 105 $ 7 L 69 1393 99 O PL 105 $ 4 L 70 3020 99 O PL 105 $ 4 L 71 3120 99 O PL 105 $ 6 L 72 2974 99 O PL 105 $ 8 L 73 3352 99 O PL 105 $ 8 L 74 3088 99 O PL 105 $ 8 L 75 3497 99 O PL 105 $ 6 L 76 2907 99 O PL 105 $ 7 L 77 2935 99 O PL 105 $ 2 L 78 4288 99 O PL 105 $ 2 L 79 3653 99 O PL 105 $ 4 L 80 3936 99 O PL 105 $ 3 L 81 3229 99 O PL 105 $ 3 L 82 2918 99 O PL 105 $ 7 L 83 3102 99 O PL 105 $ 3 L 84 4401 99 O PL 105 $ 2 L
[***] Material has been omitted pursuant to a request for confidential treatment and such material has been filed separately with the Securities and Exchange Commission. FINAL LIFECELL CUSTOMER LIST 2/9/2000 EXHIBIT D
- ----------------------------------------------------------------------------------------------------------------------------------- TAX CUST SUM OF O # CUST ID YR TYPE PECIA TER TAX AMT NAME ADDRESS CITY STATE ZIP # VS L - ------------------------------------------------------------------------------------------------------------------------------------ 85 4273 99 O PL 105 $ [***] 3 L 86 3970 99 O PL 105 $ 1 L 87 4650 00 O PL 105 L 88 9999 00 O PL 105 L 89 3410 00 O PL 106 L 90 4874 00 O PL 106 L 91 4875 00 O PL 106 L 92 4876 00 O PL 106 L 93 4877 00 O PL 106 L 94 4878 00 O PL 106 L 95 4879 00 O PL 106 L 96 4880 00 O PL 106 L 97 4881 00 O PL 106 L 98 4883 00 O PL 106 L 99 4884 00 O PL 106 L 100 4885 00 O PL 106 L 101 4886 00 O PL 106 L 102 4888 00 O PL 106 L 103 3447 99 O PL 107 $ 6 L 104 3663 99 O PL 107 $ 3 L 105 3155 99 O PL 107 $ 3 L 106 3951 99 O PL 107 $ 7 L 107 4497 99 O PL 107 $ 3 L 108 3566 99 O PL 107 $ 6 L 109 4274 99 O PL 107 $ 4 L 110 3892 99 O PL 107 $ 6 L 111 3127 99 O PL 107 $ 3 L 112 4300 99 O PL 107 $ 3 L 113 4602 99 O PL 107 $ 2 L 114 4258 99 O PL 107 $ 1 L 115 2606 99 O PL 107 $ 3 L 116 2604 99 O PL 107 $ 2 L 117 4437 99 O PL 107 $ 1 L 118 3740 99 O PL 107 $ 2 L 119 3906 99 O PL 107 $ 1 L 120 4619 99 O PL 107 $ 1 L 121 2611 99 O PL 107 $ 1 L 122 4266 99 O PL 107 $ 2 L 123 3038 99 O DM 108 $ 10 L 124 3330 99 O PL 108 $ 18 L 125 2609 99 O PL 108 $ 4 L 126 2602 99 O PL 108 $ 6 L - ----------------------------------------------------------------------------------------------------------------------------------
[***] Material has been omitted pursuant to a request for confidential treatment and such material has been filed separately with the Securities and Exchange Commission.
- ----------------------------------------------------------------------------------------------------------------------------------- TAX CUST SUM OF O # CUST ID YR TYPE PECIA TER TAX AMT NAME ADDRESS CITY STATE ZIP # VS L - ------------------------------------------------------------------------------------------------------------------------------------ 127 3727 99 O PL 108 $ [***] 9 L 128 4001 99 O PL 108 $ 6 L 129 3079 99 O PL 108 $ 9 L 130 2893 99 O PL 108 $ 7 L 131 3130 99 O PL 108 $ 12 L 132 2920 99 O PL 108 $ 21 L 133 2979 99 O DM 108 $ 4 L 134 3217 99 O DM 108 $ 3 L 135 2982 99 O PL 108 $ 6 L 136 3106 99 O PL 108 $ 5 L 137 1374 99 O PL 108 $ 1 L 138 4628 00 O PL 106 $ 1 L 139 3606 99 O PL 108 $ 13 L 140 2901 99 O PL 108 $ 4 L 141 2622 99 O PL 108 $ 4 L 142 3366 99 O PL 108 $ 10 L 143 3560 99 O PL 108 $ 5 L 144 3125 99 O PL 108 $ 7 L 145 4554 99 O PL 108 $ 2 L 146 3235 99 O PL 108 $ 2 L 147 3484 99 O PL 109 $ 13 L 148 3085 99 O PL 109 $ 13 L 149 3333 99 O PL 109 $ 7 L 150 3634 99 O PL 109 $ 6 L 151 3646 99 O PL 109 $ 3 L 152 3112 99 O PL 109 $ 1 L 153 3833 99 O PL 109 $ 4 L 154 4016 99 O PL 109 $ 2 L 155 3935 99 O PL 109 $ 3 L 156 3238 99 O PL 109 $ 4 L 157 3210 99 O PL 109 $ 4 L 158 3039 99 O PL 109 $ 5 L 159 3222 99 O PL 109 $ 2 L 160 3188 99 O PL 109 $ 4 L 161 4247 99 O PL 109 $ 1 L 162 2053 99 O PL 109 $ 2 L 163 3603 99 O PL 202 $ 3 L 164 3328 99 O PL 202 $ 6 L 165 3380 99 O PL 202 $ 5 L 166 3511 99 O PL 202 $ 4 L 167 3404 99 O PL 202 $ 9 L 168 3796 99 O PL 202 $ 2 L - -----------------------------------------------------------------------------------------------------------------------------------
[***] Material has been omitted pursuant to a request for confidential treatment and such material has been filed separately with the Securities and Exchange Commission. FINAL LIFECELL CUSTOMER LIST 2/9/2000 EXHIBIT D
- ----------------------------------------------------------------------------------------------------------------------------------- TAX CUST SUM OF O # CUST ID YR TYPE PECIA TER TAX AMT NAME ADDRESS CITY STATE ZIP # VS L - ------------------------------------------------------------------------------------------------------------------------------------ 169 4063 99 O PL 202 $ [***] [***] 2 L 170 4200 99 O PL 202 $ 2 L 171 4357 99 O PL 202 $ 2 L 172 3696 99 O PL 202 $ 4 L 173 3613 99 O PL 202 $ 4 L 174 3388 99 O PL 202 $ 2 L 175 3981 99 O PL 202 $ 1 L 176 4364 99 O PL 202 $ 1 L 177 4223 99 O PL 202 $ 2 L 178 4460 99 O PL 202 $ 1 L 179 3436 99 O PL 204 $ 15 L 180 3881 99 O PL 204 $ 9 L 181 3350 99 O PL 204 $ 12 L 182 3514 99 O PL 204 $ 6 L 183 3671 99 O PL 204 $ 6 L 184 3570 99 O PL 204 $ 10 L 185 3739 99 O PL 204 $ 6 L 186 3707 99 O PL 204 $ 4 L 187 3874 99 O PL 204 $ 4 L 188 4454 99 O PL 204 $ 3 L 189 3807 99 O PL 204 $ 2 L 190 3469 99 O PL 204 $ 4 L 191 3850 99 O PL 204 $ 1 L 192 4089 99 O PL 204 $ 2 L 193 4091 99 O PL 204 $ 2 L 194 3326 99 O PL 204 $ 3 L 195 3406 99 O PL 204 $ 3 L 196 3910 99 O PL 204 $ 4 L 197 3458 99 O PL 204 $ 3 L 198 3331 99 O PL 204 $ 2 L 199 3451 99 O PL 206 $ 11 L ###-###-#### 99 O PL 206 $ 10 L ###-###-#### 99 O PL 206 $ 4 L ###-###-#### 99 O PL 206 $ 6 L ###-###-#### 99 O PL 206 $ 5 L ###-###-#### 99 O PL 206 $ 5 L ###-###-#### 99 O PL 206 $ 5 L ###-###-#### 99 O PL 206 $ 2 L ###-###-#### 99 O PL 206 $ 2 L ###-###-#### 99 O PL 206 $ 4 L ###-###-#### 99 O PL 206 $ 4 L ###-###-#### 99 O PL 208 $ 4 L - ------------------------------------------------------------------------------------------------------------------------------------
[***] Material has been omitted pursuant to a request for confidential treatment and such material has been filed separately with the Securities and Exchange Commission. FINAL LIFECELL CUSTOMER LIST 2/9/2000 EXHIBIT D
- ----------------------------------------------------------------------------------------------------------------------------------- TAX CUST SUM OF O # CUST ID YR TYPE PECIA TER TAX AMT NAME ADDRESS CITY STATE ZIP # VS L - ------------------------------------------------------------------------------------------------------------------------------------ 211 3341 99 O PL 206 $ [***] [***] 2 L ###-###-#### 99 O PL 206 $ 1 L ###-###-#### 99 O PL 206 $ 2 L ###-###-#### 00 O PL 206 L ###-###-#### 00 O PL 206 L ###-###-#### 99 O PL 207 $ 18 L ###-###-#### 99 O PL 207 $ 28 L ###-###-#### 99 O PL 207 $ 7 L ###-###-#### 99 O PL 207 $ 7 L ###-###-#### 99 O PL 207 $ 16 L ###-###-#### 99 O PL 207 $ 9 L ###-###-#### 99 O PL 207 $ 5 L ###-###-#### 99 O PL 207 $ 4 L ###-###-#### 99 O PL 207 $ 6 L ###-###-#### 99 O PL 207 $ 3 L ###-###-#### 99 O PL 207 $ 2 L ###-###-#### 99 O PL 207 $ 4 L ###-###-#### 99 O PL 207 $ 3 L ###-###-#### 99 O PL 207 $ 3 L ###-###-#### 99 O PL 207 $ 2 L ###-###-#### 99 O PL 207 $ 11 L ###-###-#### 99 O PL 207 $ 2 L ###-###-#### 99 O PL 207 $ 3 L ###-###-#### 99 O PL 207 $ 1 L ###-###-#### 99 O PL 207 $ 1 L ###-###-#### 99 O PL 208 $ 9 L ###-###-#### 99 O PL 208 $ 14 L ###-###-#### 99 O PL 208 $ 5 L ###-###-#### 99 O PL 208 $ 7 L ###-###-#### 99 O PL 208 $ 1 L ###-###-#### 99 O PL 208 $ 1 L ###-###-#### 99 O PL 208 $ 2 L ###-###-#### 99 O PL 208 $ 5 L ###-###-#### 99 O PL 208 $ 5 L ###-###-#### 99 O PL 208 $ 1 L ###-###-#### 99 O PL 208 $ 2 L ###-###-#### 99 O PL 208 $ 5 L ###-###-#### 99 O PL 208 $ 1 L ###-###-#### 99 O PL 208 $ 2 L ###-###-#### 99 O PL 208 $ 1 L ###-###-#### 99 O PL 208 $ 1 L ###-###-#### 99 O PL 208 $ 1 L - ------------------------------------------------------------------------------------------------------------------------------------
[***] Material has been omitted pursuant to a request for confidential treatment and such material has been filed separately with the Securities and Exchange Commission.
FINAL LIFECELL CUSTOMER LIST 2/9/2000 EXHIBIT D - ----------------------------------------------------------------------------------------------------------------------------------- CUST TNX CUST SPECI- SUM OF O # ID YR TYPE ALTY TER TNXAMT NAME ADDRESS CITY STATE ZIP # VS L - ----------------------------------------------------------------------------------------------------------------------------------- 253 4860 O PL 208 [***] L ###-###-#### O PL 208 L ###-###-#### O PL 208 L ###-###-#### O PL 208 L ###-###-#### 99 O PL 209 $ 14 L ###-###-#### 99 O PL 209 $ 31 L ###-###-#### 99 O PL 209 $ 11 L ###-###-#### 99 O PL 209 $ 15 L ###-###-#### 99 O PL 209 $ 5 L ###-###-#### 99 O PL 209 $ 6 L ###-###-#### 99 O PL 209 $ 8 L ###-###-#### 99 O PL 209 $ 5 L ###-###-#### 99 O PL 209 $ 4 L ###-###-#### 99 O PL 209 $ 9 L ###-###-#### 99 O PL 209 $ 5 L ###-###-#### 99 O PL 209 $ 4 L ###-###-#### 99 O PL 209 $ 3 L ###-###-#### 99 O PL 209 $ 3 L ###-###-#### 99 O PL 209 $ 1 L ###-###-#### 99 O PL 209 $ 2 L ###-###-#### 99 O PL 209 $ 2 L ###-###-#### 99 O PL 209 $ 1 L ###-###-#### O PL 209 L ###-###-#### 99 O PL 210 $ 14 L ###-###-#### 99 O PL 210 $ 9 L ###-###-#### 99 O PL 210 $ 5 L ###-###-#### 99 O PL 210 $ 1 L ###-###-#### 99 O PL 210 $ 5 L ###-###-#### 99 O PL 210 $ 3 L ###-###-#### 99 O PL 210 $ 1 L ###-###-#### 99 O PL 210 $ 1 L ###-###-#### 99 O PL 210 $ 1 L ###-###-#### O PL 210 L ###-###-#### O PL 210 L ###-###-#### O PL 210 L ###-###-#### 99 O PL 211 $ 17 L ###-###-#### 99 O PL 211 $ 8 L ###-###-#### 99 O PL 211 $ 11 L ###-###-#### 99 O PL 211 $ 5 L ###-###-#### 99 O PL 211 $ 4 L ###-###-#### 99 O PL 211 $ 1 L ###-###-#### 99 O PL 211 $ [***] Material has been omitted pursuant to a request for confidential treatment and such material has been filed separately with the Securities and Exchange Commission. FINAL LIFECELL CUSTOMER LIST 2/9/2000 EXHIBIT D - ----------------------------------------------------------------------------------------------------------------------------------- CUST TNX CUST SPECI- SUM OF O # ID YR TYPE ALTY TER TNXAMT NAME ADDRESS CITY STATE ZIP # VS L - ----------------------------------------------------------------------------------------------------------------------------------- 295 2639 99 O PL 211 $ [***] 3 L ###-###-#### 99 O PL 211 $ 2 L ###-###-#### 99 O PL 211 $ 2 L ###-###-#### 99 O PL 211 $ 1 L ###-###-#### 99 O PL 211 $ 1 L ###-###-#### 99 O PL 211 $ 2 L ###-###-#### 99 O PL 211 $ 2 L ###-###-#### 99 O PL 401 $ 13 L ###-###-#### 99 O PL 401 $ 23 L ###-###-#### 99 O PL 401 $ 5 L ###-###-#### 99 O PL 401 $ 5 L ###-###-#### 99 O PL 401 $ 16 L ###-###-#### 99 O PL 401 $ 16 L ###-###-#### 99 O PL 401 $ 2 L ###-###-#### 99 O PL 401 $ 12 L ###-###-#### 99 O PL 401 $ 14 L 311 3353 99 O PL 401 $ 5 L ###-###-#### 99 O PL 401 $ 4 L ###-###-#### 99 O PL 401 $ 5 L ###-###-#### 99 O PL 401 $ 7 L ###-###-#### 99 O PL 401 $ 2 L ###-###-#### 99 O PL 401 $ 3 L ###-###-#### 99 O PL 401 $ 3 L ###-###-#### 99 O PL 401 $ 4 L ###-###-#### 99 O PL 401 $ 2 L ###-###-#### 99 O PL 401 $ 2 L ###-###-#### 99 O PL 404 $ 17 L ###-###-#### 99 O PL 404 $ 13 L ###-###-#### 99 O PL 404 $ 8 L ###-###-#### 99 O PL 404 $ 5 L ###-###-#### 99 O PL 404 $ 7 L ###-###-#### 99 O PL 404 $ 4 L ###-###-#### 99 O PL 404 $ 2 L ###-###-#### 99 O PL 404 $ 6 L ###-###-#### 99 O PL 404 $ 3 L ###-###-#### 99 O PL 404 $ 3 L ###-###-#### 99 O PL 404 $ 3 L ###-###-#### 99 O PL 404 $ 2 L ###-###-#### 99 O PL 404 $ 3 L ###-###-#### 99 O PL 404 $ 3 L ###-###-#### 99 O PL 404 $ 5 L ###-###-#### 99 O PL 405 $ 7 L
[***] Material has been omitted pursuant to a request for confidential treatment and such material has been filed separately with the Securities and Exchange Commission. Final LifeCell Customer List 2/9/2000 EXHIBIT D
- ----------------------------------------------------------------------------------------------------------------------------------- TAX CUST SUM OF O # CUST ID YR TYPE PECIA TER TAX AMT NAME ADDRESS CITY STATE ZIP # VS L - ------------------------------------------------------------------------------------------------------------------------------------ 337 3475 99 O PL 405 [***] [***] 9 L ###-###-#### 99 O PL 405 4 L ###-###-#### 99 O PL 405 6 L ###-###-#### 99 O PL 405 4 L ###-###-#### 99 O PL 405 4 L ###-###-#### 99 O PL 405 4 L ###-###-#### 99 O PL 405 3 L ###-###-#### 99 O PL 405 3 L ###-###-#### 99 O PL 405 3 L ###-###-#### 99 O PL 405 3 L ###-###-#### 99 O PL 405 2 L ###-###-#### 99 O PL 405 1 L ###-###-#### 99 O PL 405 2 L ###-###-#### 99 O PL 405 1 L ###-###-#### 99 O PL 405 2 L ###-###-#### 99 O PL 405 1 L ###-###-#### 99 O PL 405 2 L ###-###-#### 99 O PL 406 9 L ###-###-#### 99 O PL 406 11 L ###-###-#### 99 O PL 406 5 L ###-###-#### 99 O PL 406 7 L ###-###-#### 99 O PL 406 6 L ###-###-#### 99 O PL 406 10 L ###-###-#### 99 O PL 406 8 L ###-###-#### 99 O PL 406 2 L ###-###-#### 99 O PL 406 5 L ###-###-#### 99 O PL 406 1 L ###-###-#### 99 O PL 406 2 L ###-###-#### 99 O PL 406 3 L ###-###-#### 99 O PL 406 3 L ###-###-#### 99 O PL 406 5 L ###-###-#### 99 O PL 406 1 L ###-###-#### 99 O PL 406 1 L ###-###-#### 99 O PL 406 3 L ###-###-#### 99 O PL 406 3 L ###-###-#### 99 O PL 406 2 L ###-###-#### 99 O PL 406 2 L ###-###-#### 99 O PL 406 3 L ###-###-#### 99 O PL 406 1 L ###-###-#### 99 O PL 407 14 L ###-###-#### 99 O PL 407 5 L ###-###-#### 99 O PL 407 10 L - ------------------------------------------------------------------------------------------------------------------------------------
[***] Material has been omitted pursuant to a request for confidential treatment and such material has been filed separately with the Securities and Exchange Commission.
- ----------------------------------------------------------------------------------------------------------------------------------- TAX CUST SUM OF O # CUST ID YR TYPE PECIA TER TAX AMT NAME ADDRESS CITY STATE ZIP # VS L - ------------------------------------------------------------------------------------------------------------------------------------ 379 3814 99 O PL 407 [***] [***] 9 L ###-###-#### 99 O PL 407 10 L ###-###-#### 99 O PL 407 6 L ###-###-#### 99 O PL 407 3 L ###-###-#### 99 O PL 407 4 L ###-###-#### 99 O PL 407 3 L ###-###-#### 99 O PL 407 5 L ###-###-#### 99 O PL 407 2 L ###-###-#### 99 O PL 407 2 L ###-###-#### 99 O PL 407 1 L ###-###-#### 99 O PL 407 1 L ###-###-#### 99 O PL 407 1 L ###-###-#### 99 O PL 408 70 L ###-###-#### 99 O PL 408 17 L ###-###-#### 99 O PL 408 15 L ###-###-#### 99 O PL 408 4 L ###-###-#### 99 O PL 408 21 L ###-###-#### 99 O PL 408 7 L ###-###-#### 99 O PL 408 8 L ###-###-#### 99 O PL 408 14 L ###-###-#### 99 O PL 408 5 L ###-###-#### 99 O PL 408 2 L ###-###-#### 99 O PL 408 7 L ###-###-#### 99 O PL 408 4 L ###-###-#### 99 O PL 408 4 L ###-###-#### 99 O PL 408 5 L ###-###-#### 99 O PL 408 2 L ###-###-#### 99 O PL 408 6 L ###-###-#### 99 O PL 408 6 L ###-###-#### 99 O PL 408 2 L ###-###-#### 99 O PL 408 1 L ###-###-#### 99 O PL 408 1 L 411 4632 00 O PL 408 L ###-###-#### 99 O PL 408 L ###-###-#### 00 O PL 408 L ###-###-#### 00 O PL 408 L ###-###-#### 00 O PL 408 L ###-###-#### 99 O PL 409 6 L ###-###-#### 99 O PL 409 5 L ###-###-#### 99 O PL 409 6 L ###-###-#### 99 O PL 409 9 L ###-###-#### 99 O PL 409 7 L - ------------------------------------------------------------------------------------------------------------------------------------
[***] Material has been omitted pursuant to a request for confidential treatment and such material has been filed separately with the Securities and Exchange Commission.
- ----------------------------------------------------------------------------------------------------------------------------------- TAX CUST SUM OF O # CUST ID YR TYPE PECIA TER TAX AMT NAME ADDRESS CITY STATE ZIP # VS L - ------------------------------------------------------------------------------------------------------------------------------------ 421 3558 99 O PL 409 [***] [***] 2 L ###-###-#### 99 O PL 409 3 L ###-###-#### 99 O PL 409 4 L ###-###-#### 99 O PL 409 6 L ###-###-#### 99 O PL 409 7 L ###-###-#### 99 O PL 409 4 L ###-###-#### 99 O PL 409 3 L ###-###-#### 99 O PL 409 2 L ###-###-#### 99 O PL 409 1 L ###-###-#### 99 O PL 409 1 L ###-###-#### 99 O PL 409 1 L ###-###-#### 99 O PL 409 2 L - ------------------------------------------------------------------------------------------------------------------------------------
Total count for LifeCall List = [***] Material has been omitted pursuant to a request for confidential treatment and such material has been filed separately with the Securities and Exchange Commission. EXHIBIT E PRODUCT STORAGE, HANDLING AND TRANSPORTATION SPECIFICATIONS AND PROCEDURES The following policies and procedures are based on the Standards of the American Association of Tissue Banks (1996) and specifically address the issue of "Tissue Distribution Intermediates" (Section M). Technical assistance is available from LifeCell to facilitate the incorporation of these procedures. Appropriate documentation is critical. Particular attention should be paid to the following areas: Documentation of receipt of tissue Lot/graft numbers Expiration date Received by Date of receipt Condition of packaging Documentation of storage conditions Temperature monitoring Documentation of distribution Date of order Consignee name and address Identification of person placing the order Type and quantity of tissue ordered Information regarding tissue shipped Identification number(s) of tissue(s) Expiration date of tissue Date of shipment Mode of transportation Name of Individual filling order Documentation of final package inspection prior to distribution ADDITIONAL REQUIREMENTS: STORAGE EQUIPMENT All storage equipment (i.e., refrigerator(s)) must be regularly maintained (i.e. preventative maintenance program)), calibrated, and monitored. Monitoring of refrigerators may consist of the installation of a continuous temperature recording device or a routine (once each working day) and DOCUMENTED check of temperature utilizing a refrigerator thermometer. Acceptable temperature range for the storage of Products is 2 - 8DEG.C. Products may be stored in a standard household refrigerator provided that this temperature range can be maintained. -5- ADVERSE OUTCOMES All reports of complaints or adverse outcomes must be required to be forwarded immediately to LifeCell. RETURN OF TISSUE All expired, returned, damaged, or otherwise compromised packages or grafts must be returned to LifeCell. TRANSPORTATION Products may be shipped to customers by commercial overnight courier services without adherence to any of the product storage and handling policies and procedures set forth in this EXHIBIT A. -6-